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Introduction: There is a lack of policies and research regarding the disclosure of results in genomic 
research, especially in South Africa. Challenges remain regarding the disclosure of genomic 
research results to research participants and their families, which may partly be addressed by 
considering parental and participants’ preferences. This study serves as a sub-study to the 
NeuroDev study which is performing genotyping and exome sequencing on children with 
NeuroDevelopmental disorders in the Western Cape; and will investigate a feedback of findings 
method pertaining to the needs and preferences of the patient community. 
 
Aims: To investigate parents’ understanding of the genomic research study they are participating 
in as well as their preferences regarding the feedback process and anticipated contributions of 
significant genetic findings generated by the NeuroDev study. This study further hopes to inform 
a tailored feedback policy reflecting the needs of this South African population. 
 
Research Design: A pragmatic qualitative approach was used by conducting 12 semi-structured 
interviews with 17 parents of children participating in the NeuroDev study. Purposive sampling 
was used, selecting retrospectively from patients recruited for the NeuroDev study in which 
findings of de novo, significant mutations are more likely expected. Interviews were conducted in 
English, in a private setting at Red Cross War Memorial Children’s Hospital (RCWMCH), and 
were audio-recorded by the researcher; observations and field notes were documented. 
Generated data was analyzed using thematic analysis to generate themes and transcripts 
were imported into NVivo 12 to assist with managing and organizing the data for analysis. Ethical 
approval was been obtained from the University of Cape Town (UCT) (HREC 784/2018).   
 iii 
 
Results: Empiric data collection ran from May to July 2019 and preliminary data was presented 
at the NeuroDev AGM and on a poster at the SASHG conference, RCWMCH research open day 
and UCT postgraduate research day. Findings were that the parents of the participants 
understood the study they were participating in as well as basic concepts of genetics, however, 
parental understanding over the cause of their child’s condition remains a source of confusion 
when pertaining to their understanding of genetics being ‘passed down the family lineage’ and 
how that integrates with de novo mutations. Furthermore, there is potential for it to impact on 
feelings of guilt. Parents have a need for information, discovering the cause of their child’s 
condition and to be involved in the research process with full disclosure as events unfold. Altruism 
seems to be a major motivator for participating in genomics research but personal and family 
benefit also served to be a key driver in that research results could potentially provide awareness 
and information regarding their child’s condition, the management thereof and recurrence risk in 
future. Participants in this study want pertinent research results which could offer closure, 
acceptance and relief, however, differences over the meaning of such results were observed 
between those whose child already had a diagnosis versus those whose child remained 
undiagnosed. Furthermore, receiving non-pertinent and negative result was still perceived to be 
meaningful for some. Further diversity was observed in parental preferences for the explanation 
of preliminary results. 
 
Discussion: Given that non-pertinent results still hold value for participants, consideration should 
be given as to more extensive ways of communicating this if such results are not to be returned 
since results are generally viewed as a point of access to information or relating to their child’s 
condition. Diverse preferences regarding when and what participants want to know for results 
feedback needs to be addressed in order to facilitate a guidance framework for the delivery of 
genomic research results and can perhaps take the form of a tiered-consent model for feedback 
of incidental findings. As such, genetic counsellors may have a valuable role to play in facilitating 
participant satisfaction and bridging the gap between researchers and public expectations. 
 
Ethical considerations: Consent was taken before commencement of the study. There were no 
risks with regards to participating in this study and participants had the freedom to withdraw at 
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“Love is the only way to grasp another human being in the innermost core of his personality. No 
one can become fully aware of the very essence of another human being unless he loves him. 
By his love he is enabled to see the essential traits and features in the beloved person; and 
even more, he sees that which is potential in him, which is not yet actualized but yet ought to be 
actualized. Furthermore, by his love, the loving person enables the beloved person to actualize 
these potentialities. By making him aware of what he can be and of what he should become, he 
makes these potentialities come true.” 
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1 CHAPTER 1 INTRODUCTION 
 
Genomics research on mental health conditions and NeuroDevelopmental disorders (NDDs) is 
gaining traction in South Africa (SA) with various projects being conducted at University of Cape 
Town (UCT) such as the Genetic Characterization of Neuro-Developmental Disorders in South 
African Populations (NeuroDev) study and projects falling under the Human Heredity and Health 
in Africa (H3Africa) Consortium. 
 
One pertinent challenge in genomics research relates to questions about what to do with research 
results that are relevant to the health of the participant. Deciding whether to disclose individual 
genomic research results, and the researcher’s obligations in this regard, has been the topic of 
much controversy nationally and internationally, particularly where minors are concerned. 
With the advent of whole-exome and whole-genome sequencing technologies, the identification 
of unintended, incidental findings (IF) as well as variants of uncertain significance (VUS) is 
inevitable. In many cases, determining what results mean for the patients and whether they are 
actionable remains a formidable task. 
 
With the exception of the H3Africa feedback of findings (FoF) guidelines, few other policies and 
little research exists regarding the disclosure of research results to research participants in SA. 
The goal of this study was to investigate preferences for the FoF pertaining and tailored to the 
needs of a South African (SA) patient community. In the context of ongoing genomics research 
being conducted through the NeuroDev study at the Red Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town, there would then be potential for such needs to be recognized and 
policies to be informed. 
 
The NeuroDev study is a large-scale, international collaborative study which aims to map genetic 
variation amongst children with NDDs by performing genotyping and exome sequencing on 
children aged 2 – 17 years old, with NDD.  Although a lot has been written about the return of 
incidental or secondary findings in genomics research, in this research I will focus only on the 
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disclosure of pertinent genomic research results (ACMG, 2013a; Ortiz-Osorno, Ehler & Brooks, 
2015). The NeuroDev study will be returning results that are currently known to be pathogenic 
and associated with ASD and ID and as such, with the child’s condition. In other words, these are 
findings that are currently included in existing, validated diagnostic tests. In the empirical work for 
this thesis, I sought to understand better how and when these results ought to be fed back. 
 
To assist in examining the role of the genetic counsellor (GC) and achieve the above-mentioned 
goals, this study will present findings of a qualitative research study conducted in the Western 
Cape (WC) on NDDs that focused on how to map participants’ expectations and preferences for 
feedback. Insights gained in the research project will be used to explore the role that GCs could 
play in the return of pertinent genetic research results in genomics research and suggest elements 
of best practice for consideration. It will do so by engaging with enrolled participants to explore 
how this component of the study is explained and understood, and what patient preferences are 
for the return of results (RoR).The overall aim of this proposed study is to support the design of a 
returns policy for pertinent genomic research results for the NeuroDev study, which could possibly 
be of wider use to other genomic research being conducted at UCT. 
 
 DISSERTATION CHAPTER OUTLINE 
 
I have thus far provided a brief introduction to my dissertation in “Chapter 1” above. As a guide to 
the reader, I provide the following as an outline to the chapters that will commence. 
To start off, this project aimed to investigate parents’ perspectives and preferences regarding the 
feedback process of genomic research results obtained during the NeuroDev study and the 
anticipated contributions of such findings and as such, focuses on three main research questions, 
namely, what NeuroDev research participants consenting to the return of positive individual NDD-
related genetic results understand from the study to which they have consented, their reasons for 
agreeing to the return of positive individual NDD-related genetic results, and recommendations 
for how positive NDD-related individual genetic research results can best be fed back to research 
participants. These question have been used to guide my search for empiric data and to frame 
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my literature review, and I have aimed to structure my findings accordingly in order to answer 
these questions. 
"Chapter 2 – Literature Review”. In this chapter I will look at the key features and considerations 
for the return of genomics research results as well as how this relates to paediatric research and 
existing empirical. I provide an overview of international and SA-specific guidelines for the return 
of genomic research results and sketch a background on NDDs and the current clinical practice 
employed in diagnosing or testing for this group of disorders. I then focus on the NeuroDev study, 
providing insights into their feedback policy, aims, rationale and questions outstanding. 
“Chapter 3 – Research Methodology”. In this chapter I provide you with the study design used to 
conduct this qualitative research study, participant background, the recruitment process and the 
research procedure, data collection and analysis methods. Furthermore, ethical considerations 
are discussed with respect to informed consent, privacy and confidentiality and risks and benefits 
to participants. 
The next three chapters (4, 5, and 6) will focus on the results of this study. The first of three 
findings chapters is “Chapter 4” which informs my first research question of how participants 
consenting to the return of individual pertinent research results understand what they have 
consented  to. 
“Chapter 4 – Participant understanding, expectations and reasons for partaking in genomic 
research”. In this chapter I also provide the sociodemographic data of my study participants and 
what people want to know on a generic level. 
“Chapter 5 – Pertinent Results is the second of three findings chapters”. This aims to answer my 
research question regarding why participants agree to the return of pertinent research results. 
The last of three findings is “Chapter 6 - Preference to feedback”. Here I explore participant 
preferences to the feedback of genomic research results and recommendations on how best to 
feedback such results, informing my last research question. 
The final chapter of the dissertation is “Chapter 7 – Discussion”. This chapter will provide a 
landscape of findings from this study, highlighting prominent concepts pertaining to participant 
preferences in the return of genomic research results and how it can inform such disclosure as it 








2 CHAPTER 2 LITERATURE REVIEW 
 
2.1 RETURN OF INDIVIDUAL GENETIC RESEARCH RESULTS IN GENOMICS  
 
Next generation sequencing (NGS) has become  cost-effective and accessible in the field of 
genomic research, allowing for its use in research to extend from testing preselected genetic 
sequences to testing the entire genome. Whole exome sequencing (WES) and whole genome 
sequencing (WGS) are two methods that employ NGS. Whilst WGS analyzes the entire genome 
of an individual, WES allows for only the protein coding region of the genome to be analyzed and 
is less costly and time-consuming. WES detects rare protein truncating (loss of function) variants, 
found to be strongly associated with intellectual disability (ID) and autism spectrum disorders 
(ASD) in which the variant may be inherited or have arisen de novo. Such variants are reported 
to be present in at least 13% of cases with ASD and severe NDD phenotypes (Kosmicki et al., 
2017). WES/WGS offer the potential to change clinical management and intervention strategies 
should an underlying genetic causative variant for NDDs be found. Furthermore, microarray 
analysis may be employed and is often used for genotyping in genomic research, allowing for the 
examination of the distribution and effects of risk conferring rare copy number variants (CNV) 
such as deletions or duplications that are often strongly associated with NDDs (Miller, David et 
al., 2010; Schaefer & Lutz, 2006). 
 
However, with the increased use of NGS in research as well as clinical practice, IF and VUS are 
inevitable and interpretation of pathogenicity remains difficult and uncertain, complicating the 
process of returning results to research participants. This has fostered ethical debate worldwide 







2.1.1. KEY FEATURES OF THIS DEBATE 
 
A vast amount of genetic data is being generated using NGS technologies, emphasizing the need 
for clearly established policies about the disclosure of individual genetic research results. An 
intricate debate centres primarily around the nature of the result and the ensuing genetic 
information, with numerous terms and concepts used to define the nature of results with the aim 
of eliminating confusion and providing guidance for disclosure to researchers (Eckstein, Garrett 
& Berkman, 2014). Further adding to researcher confusion, dispute continues over the extent of 
researcher obligations in disclosing genetic research results.  
 
Researchers are expected to classify between IF/secondary findings, ensure analytic validity and 
determine the clinical validity of a result which is complicated by phenotypic heterogeneity, gene 
penetrance, small study populations, and phenotypic modifiers (to name a few). Additionally, 
varying interpretations of a result may ensue depending on the reference system used by the 
researcher, which elicits differing views/opinions regarding the clinical utility of a result. 
 
Disclosure should include results which are 1) clinically significant which improve treatment, 
prevention, or understanding of a disease for a participant or their relatives (Miller et al., 2008; 
Shalowitz, David & Miller, Franklin, 2008; Shalowitz & Miller, 2008) – these are suggested to be 
linked to the preferences of patients given that the benefits of knowledge, albeit painful, are 
shaped by personal views and values; and 2) clinically relevant, a concept which closely 
resembles clinical significance, but Kohane and Taylor suggest a greater knowledge of the 
participants’ history, family and environment may help distinguish results and their associations 
from “interesting” variants (Kohane & Taylor, 2010). Pullman and Hodgkinson note that factors 
such as age, gender, medical history and the health behaviours of participants may influence 
which results are assigned clinically relevant (Pullman & Hodgkinson, 2006). Furthermore, the 
variety of genomic research being conducted, the types of participants contracted (for example, 
patients and healthy volunteers), the scope of genetic information (being validated or non-
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validated, highly or poorly predictive, more or less probabilistic genetic data), and of the research 
add further complexity (Bredenoord et al., 2011). 
 
Further distinction needs to be made between findings that are pertinent, IF and VUS when 
considering results disclosure. Pertinent findings are those which answer particular clinical or 
research questions and have been purposefully sought by genotyping specific areas of the 
genome or by specifically interrogating specific areas previously generated by WGS. These are 
primary findings/mutations, known to be pathogenic in origin and recognized to cause the disorder 
under investigation (Hall, Hallowell & Zimmern, 2013). IF relate to those unexpected, additional 
findings discovered during clinical or research investigations which have potential health 
implications and clinical significance. These findings are beyond the scope and aims of the 
research or requested test, were not actively sought during the research process (Hall, Hallowell 
& Zimmern, 2013) and are usually not disclosed to the participant or related clinician. VUS results 
relates to those in which a genotype-phenotype relationship cannot be statistically and 
scientifically established and there is a paucity of evidence to support the relationship between 
the variant and the phenotype (Hall, Hallowell & Zimmern, 2013). 
 
Dispute concerning definitional/terminological uncertainty arises possibly due to varied beliefs 
regarding the distinction between research and clinical care, thereby impeding the formulation of 
a disclosure framework (Eckstein, Garrett & Berkman, 2014). The differences between the return 
of individual research results and the RoR in the clinical setting lie in the curatorship of samples 
(ensuring the sample belongs to the correct participant) as well as the obligations towards 
participants and their families. There is still much uncertainty regarding how the preferences of 
participants and their families are taken into account (during and after consent); to whom the 
results should be disclosed; and when and what the extent of researcher obligations are in terms 
of disclosure (Harris, Erin et al., 2012; IRCM Working Group, September 2015). Researchers 
need to fulfill their obligations for the disclosure of pertinent individual research findings but the 
need to protect participants and their parents from undue related harm (such as anxiety and 
privacy) remains a priority. This is challenging in the research setting, especially concerning 
paediatric research where the parents and the minors’ right-to-know or not know about findings 
must be respected and remains a topic of controversy (IRCM Working Group, September 2015). 
Furthermore, results obtained in a research setting need to be validated by an accredited or 
certified laboratory before being returned to research participants. This may be costly, return may 
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require extra skills and more man-power, and an infrastructure and tight budget may not allow for 
individual RoR in a research setting. Clinical genetic results are obtained from an accredited 
laboratory and the medical professionals who deliver these results to their patients ideally have 
expertise in their field with access to multidisciplinary teams. These medical professionals have 
an obligation to return clinical results to their patients and have the means and access to 
implement management and/or therapeutic interventions. Whilst formal consent for testing is 
taken in such a setting and testing is done specifically to give results if there are any, the 
preference of the participants may not always play a role after consenting as the medical 
professional has a duty to disclose results, especially those which are believed to be clinically 
actionable, regardless of the individual’s choice not to know (Harris, Erin et al., 2012; IRCM 
Working Group, September 2015). 
 
All-embracing, three common concepts are identified in all ethical disagreements regarding the 
disclosure of individual genetic research results. These are validity, value and volition which form 
part of a tripartite framework (3V framework), which Eckstein et al. suggest as a disclosure 
framework to a general application of research findings without the distinction between primary 
and secondary findings (Eckstein, Garrett & Berkman, 2014). While validity and value focus 
primarily on the nature of the information, volition pertains to the individual to whom such 
information will be disclosed and whether they want the information or not.  
 
2.1.1.1 WHY IS THIS AN ISSUE 
 
Genomic research results are predictive of participants’ future health, could impact on their 
reproductive choices, and may have implications for their family members as well. Notably, 
disclosure can influence the individual’s ability to obtain health insurance and may expose him/her 
to stigmatisation or ostracisation from family or society. This is to say that the individual’s genomic 
information may affect their self-related or perceived personal identity and they may further 
experience being dissociated from a cultural/ethnic group or other inclusion group with which they 




Furthermore, participants entrust their health to the researchers during the time research is 
conducted and hence the nature of researcher-participant relationship is influenced by the 
duration and intensity of such research, which in turn may influence the extent of the duty to offer 
results. Offering results could foster productive partnerships between researchers and 
participants such as evoking long-standing commitment to the research study. This being said, 
questions of fairness and discrimination may be raised when participants find themselves taking 
part in a study where they feel they have no relationship or contact with the researchers and that 
they may not have equal treatment or consideration (Bredenoord et al., 2011). 
 
Apart from the impact on the individual participant, disclosing research results to  individuals  may 
place burden on the research enterprise. It requires expertise and skills that may not be feasible 
within a particular research setting and lack of infrastructure may limit the range of actionability 
from one research setting to the next. This remains evident in an African research setting (Rotimi 
et al., 2014). 
 
Genomic research results have implications for society as a whole since people have the 
opportunity to understand genomic contribution to disease and health, thereby being better placed 
to gain relevant skills and knowledge relating to conditions. Disclosure can support public 
understanding of the importance of research in healthcare, provide education regarding the 
complexity of genetic findings, and offer more involvement through offering a more active 
engagement in biomedical research. 
 
The inevitability of IF can exacerbate issues of privacy and confidentiality, personal decision-
making, and ethical obligations of researchers and clinicians (Sapp et al., 2014) and disclosure 
remains somewhat of an ethical controversy. It is clear, however, that consensus should be 
reached regarding the RoR and guidelines/policies implemented to guide healthcare 
professionals with such interpretation and disclosure (Holm et al., 2014; Sapp et al., 2014). A 
balance between showing respect for participant preferences, maximizing potential benefits from 
the knowledge, determining and reducing medical and psychosocial harm to participants, 
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ensuring accurate and comprehensible results, and burdens on the research enterprise needs to 
exist. Participant autonomy should be permitted, allowing individuals to indicate and exercise their 
preference for which results they would want to receive about their children and themselves (Holm 
et al., 2014). 
 
2.1.2 KEY CONSIDERATIONS 
 
2.1.2.1 PATHOGENICITY AND SCIENTIFIC EVIDENCE 
 
Determining pathogenicity of a finding can be complex and relies on scientific, robust statistical 
evidence of what the function of the gene is (genomic characteristic) and how it links to a particular 
phenotype, and genomic databases produced from previous investigations and literature.  Known 
pathogenic variants are those previously reported on and recognized to be the cause of a 
condition. However, if the representativeness of the sample on which those databases are based 
is too small or inadequately representative of different groups of people, these “lists” are likely to 
be incomplete. That is to say, pathogenicity is often based on a judgement which includes 
understanding what the gene may do, where it is positioned, whether it has been described 
before, the child’s phenotype and so forth. The degree of certainty is assessed through the 
availability of such above-mentioned scientific evidence before reporting on such findings (Hall, 
Hallowell & Zimmern, 2013). VUS’ are generally not reported on as these are deemed not clinically 
actionable since their relevance is uncertain and the course of clinical management of the patient 
is unlikely to change. The meaning of a VUS may change in the future as new data emerges, 
however, most research studies are under no obligation to continue interrogation of a VUS’ 








2.1.2.2 AUTONOMY AND CONSENT (VOLITION) 
 
Autonomy relates to the participant’s ability to decide for themselves about whether to participate 
in a research study. The issues that are faced nowadays pertain to the right of the participant to 
exercise their autonomy and state their preference regarding which findings resulting from the 
research study they would like to receive, which can only be appropriately decided if information 
is clearly conveyed to them and well-understood, and should be established during the process 
of a well-executed informed consent. 
 
Ortiz-Osorno et al., McGuire and Beskow propose that a tiered approach re-contacting 
participants for consent to receive feedback on certain findings can promote autonomy and well-
being of participants, can permit participants to set their preferences with regards to which type 
of results they would want to receive, and can be useful in informed consent in genomics and 
genetic research (McGuire & Beskow, 2010; Ortiz-Osorno, Ehler & Brooks, 2015). Ortiz-Osorno 
and colleagues feel that a participant’s choice should be respected and that their decision bears 
weight and importance, regardless of the nature of the research finding. The actionability versus 
the non-actionability of the result impacts on the weight of the participant’s decision and hence 
their preference to know or not know about the finding. They further state that, in accordance with 
Helgesson, with the concept of autonomy being a continuum of information a participant chooses 
to know or not know about, a participant has the right through autonomy to choose what findings 
they want to know or not know about (Helgesson, 2014). Knoppers and colleagues (2014) state 
that research findings that relate to the current or future health or quality of life of the participant 
should be offered to participants and their wish to not receive information should be respected 
(Knoppers, 2014). Others argue that researchers’ obligations of a ‘duty to warn’ and a ‘duty to 
rescue’ precede the concept of autonomy and that participants should be re-contacted with 
research results that carry implications in lieu of their decision to opt-out of feedback (ACMG, 








2.1.2.3 PARTICIPANT SATISFACTION 
 
Novel genetic information is a constant discovery in genomic research, but such research now 
offers individuals the opportunity to receive results which may have meaning to them and thus 
receiving such results may be desirable to research participants. In studies conducted by Harris 
et al. and Kauffman et al. (Harris, et al., 2012; Kaufman et al., 2009), participants express their 
desire to receive research results, and Wolf et al. found that they feel they have a right to 
information generated by such research, which may have implications for their health (Wolf, 2012; 
Wolf et al., 2012). 
In a research setting, unlike a clinical one, researchers have no duty to return research results. If 
such return is offered, guidelines by the Presidential Commission for the Study of Bioethical 
Issues (2013) suggest that the investigators should allow participants the option of opting out of 
receiving results (Presidential Commission for the Study of Bioethical Issues, 2013). Many 
different models have since been developed in an attempt to generate participant satisfaction 
(Bacon et al., 2015; Holm et al., 2015). 
Incorporating preferences into the strategy for the return of research results remains a challenge 
and in doing so the participant’s true desires regarding the information they want to receive needs 
to be reflected. It is evident from the literature that participants want to have a choice, but how 
granular must these choices be, and is just having a choice – any choice – the salient factor? It is 
unclear from the literature whether participants truly understand the implications of their choice 
regarding which results to receive and whether these choices are lucid and valid (Wolf, 2012). Of 
course, implementing preference-based models is costly and not always feasible given that 
participants need to be adequately educated about the types of results they could receive to 
enable informed choices.  
 
Holm et al. (2015) and Christensen et al. (2017) described that greater participant satisfaction 
concerning the process of feedback of results may be achieved by ‘allowing research participants 
to set preferences about the kinds of conditions they would want disclosed’ rather than simply 
providing no options or binary options about whether disclosure should even occur (Holm et al., 
2015; Christensen et al., 2017). They further argue that this may not necessarily require the 
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infrastructure needed to explain the different types of results to participants. Participants may 
have different perspectives to researchers and healthcare practitioners and may classify disease 
characteristics such as actionability and severity differently. According to Holm (2015) and 
Christensen et al. (2017), satisfaction appeared to be associated with benefits of information (i.e. 
participant reasons for wanting information) rather than harms (reasons for not wanting 
information). Benefits of knowing, as described by the participants included preparing for the 
future, having more control over the future, preventing worry, and seeking medical treatments 
(Holm et al., 2017). Participants’ expectations about disclosure may be better met by matching 
preference-setting options with examples of conditions (Christensen et al., 2017). Studies have 
shown that research participants are more concerned about results that are important and health-
relevant being withheld than they are about receiving unexpected, unsolicited information and its 
potential harms. When deliberating results disclosure approaches, satisfaction is only one 
component amongst many that needs consideration when evaluating the potential benefits and 
harms to participants (Wolf, 2012) and ethical arguments considering the implementation of 
participant preferences may carry much weight (Kollek & Petersen, 2011). 
 
2.1.2.4 CONTEXT OR SETTING 
 
Genomic research results cannot always be generalized from one context to another. As such, 
researchers need to be aware of the environmental context of their research setting, the culture 
influenced by such research and the availability of resources such as time and finances. 
Researchers may find the need to collaborate with international partners in order to finance the 
study or attain access to technologies or develop genomic databases. Besides infrastructure, 
researchers need to be cognisant of the community and participants’ colloquialism, beliefs, 
education levels and personal circumstances which may serve as barriers to accessing 









2.1.2.5 ETHNOCULTURAL LENS 
 
Contextualization in disclosing genomic research results remains fundamental, even more so in 
a community like SA that is linguistically and culturally diverse (Munung et al., 2016; Nembaware 
et al., 2019; Tekola et al., 2009b). Understanding of genetics and concepts of heredity may be 
challenged by cultural beliefs and may require adjustment to means of communicating such 
information, especially since equivalent terms or concepts are often not available colloquially. 
Awareness of individual/community background or circumstance can ensure sound 
understanding and acceptance and promotes emotional well-being of participants and adaptation 
to genetic information (Tekola et al., 2009b). 
 
2.1.2.6 ROLE OF THE GENETIC COUNSELLOR 
 
The role of the GC in the feedback of genomic research results is particularly important, especially 
in the interpretation of the data and where unexpected findings are revealed. The GC is trained 
in the capacity to discuss risks, expectations, benefits and limitations of testing and has the skills 
to communicate the implications of this information to clinicians and their participants in ways that 
positively affect adaptation and behaviours to receiving genetic information (Joseph, 2018). A GC 
can assess risk to the participant and their family members, including risk of inheriting the 
condition and the risks to future pregnancies. They can assist with pregnancy planning options 
and help implement and coordinate appropriate management and surveillance plans for those at 
risk. 
 
GC’s have a sound background knowledge in genetics, work closely with clinical geneticists and 
a multidisciplinary team, and have the experience of dealing with genetic/genomic results and 
conditions. Furthermore, GCs understand the importance of ‘wearing an ethnocultural lens’ when 




2.2 CONSIDERATIONS FOR THE RETURN OF PAEDIATRIC RESEARCH 
RESULTS 
 
2.2.1 EMPIRICAL STUDIES ABOUT PARENTAL PREFERENCES 
 
Participant preferences are subject to change as their personal or family circumstances influence 
these choices and are intimately linked to the values and norms of the participant, the nature of 
which may change as the information a participant has at hand changes at any given time (Harris 
et al., 2012). This leaves researchers with the difficult task of attempting to deal with participant 
future preferences. The importance of effective communication between researcher and 
participant could alleviate some of the complications that may arise from this uncertain 
changeable factor that could influence research (Eckstein, Garrett & Berkman, 2014; Kohane & 
Taylor, 2010). Matsui et al. hence suggest that proper procedures be put in place at the beginning 
of the research, to ascertain and secure participant preferences for future contact and disclosure 
(Matsui et al., 2008). 
 
Eckstein and colleagues (2014), suggest that volition serves a gate-keeping role in decisions 
regarding disclosure of results. So while a participant might decide that he/she wants to receive 
feedback on research findings, the validity and value of these findings first need to be assessed 
before the participant’s preference is adhered to (Eckstein, Garrett & Berkman, 2014). 
 
Unique to a paediatric setting, is that parents are faced with difficult decisions as to whether they 
would want to receive secondary, unanticipated findings that could be predictive of adult-onset 
conditions, in addition to the other questions already raised. 
In a study investigating the preferences, attitudes, values and beliefs of parents of children with 
undiagnosed, rare conditions undergoing exome sequencing, Sapp et al. (2014) found that 
parents are willing to ‘learn and assimilate’ new information such as secondary findings, 
regardless of its relationship to the condition. There were, however, limitations to what they 
wanted to learn and not all attitudes were positive to receiving any and all information (Sapp et 
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al., 2014). Additional studies have shown a generally positive attitude regarding the receipt of all 
types of information generated, however, the values and beliefs that inform participants’ attitude, 
as well as whether these pertain to parents of affected children undergoing exome sequencing to 
identify a possible genetic cause contributing to their child’s condition, remains to be studied 
(Harris et al., 2012; Ziniel et al., 2014). By understanding parental preferences, and their 
underlying beliefs and values, informed choice can be facilitated through ‘designed intervention’ 
(Sapp et al., 2014). The study conducted by Sapp et al. found that parents seemed to want 
actionable results and weighed the benefits of learning secondary results against the 
consequences of knowing. Actionability is the potential for knowledge of the finding to lead to 
some kind of action and controversies arise regarding its definition. Terry (2012) defines 
actionability in relation to the availability of treatment or prevention, whereas others take a 
participant-centered approach including into the definition the possibility for an improved health 
outcome (NHLBI Working Group; 2010) and the need to understand actionability from the 
participant’s perspective (Wolf et al., 2015). Results from focus group discussions in the United 
States (U.S.) reported the following inclusions by members of the public: ‘1) getting treatment and 
prevention, 2) informing family members of their risk, 3) making reproductive decisions, 4) working 
for environmental action or remediation, 5) life and financial planning, and 6) participating in 
further research’ (Sapp et al., 2014). Parents valued the importance of knowing but wished to 
preserve their child’s autonomy in situations where few available treatments or prevention existed. 
Parents felt they had managed to adapt and cope with the uncertainty of their child’s condition 
and were not intimidated by unexpected information. This was due to personal lived experience 
of having a child with a rare and undiagnosed condition.  The parents from this study valued 
choice – being able to convey their preference regarding what information they wanted to learn 
about themselves and their child – and embraced the opportunity to consider their options and 
the implications (Sapp et al., 2014). Similarly, research conducted by Ziniel et al. (2014) showed 
that most parents wanted to receive individual research results but some were more selective and 
wanted a choice over which types of results they would receive, demonstrating a desire for control. 
These findings were reiterated in study findings by Harris et al. (2012) who additionally observed 
that participants expected to receive contextual information along with their child’s research 
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results to assist them in the interpretation of the results and direct them to appropriate resources 
which would aid in gathering more information, especially when these findings are of unclear 
significance. Such contextual information includes resources which explain the results in detail, 
links to relevant literature, and recommended future direction, experts who could help interpret 
results or support groups. Tabor and colleagues (2011) found that parents of children with autism 
and diabetes who were participating in research were interested in receiving results for their 
children related to adult-onset conditions, regardless of the potential for negative psychological 
impact. Their reasons for this stemmed beyond the clinical utility of such results, including an 
explanation of disease etiology and psychological benefits. Interestingly, only parents of children 
with autism included reasons of reproductive decision-making for themselves, their unaffected 
children and extended family. They desired an explanation as to the cause of their child’s autism 
and an answer to why it happened. These reasons related to their personal utility of results 
information (Tabor et al., 2011). As such, the perceptions of parents regarding the risks and 
benefits of receiving research results may differ amongst parents in different research contexts, 
i.e. where different conditions are being investigated (Tabor et al., 2011). For this reason, Miller 
et al. (2010) suggest that disclosure standards remain specific to disease contexts, giving 
consideration to the position of concurrent debates centering around the nature and cause of a 
given disorder as well as justifying such results with clarity regarding the appropriate standards 
of evidence because the meaning of the results to research participants differ across these 
contexts (Miller et al., 2010). 
A study conducted by Christensen et al., (2017) found that parents of potential research 
participants show ‘greater likelihood of having more nuanced preferences about genetic 
information disclosure than those patients who undergo clinical sequencing personally ’. In this 
study, there appeared to be an overall trend for more information. Furthermore, it was also noted 
that research participants are more likely and willing to defer to experts (such as doctors) when 
the value of results is not well-understood and when facing the uncertainty and limited utility of 
disclosed results and under the circumstances of results uncertainty, their preferences for RoR 
are likely to change (Christensen et al., 2017).  
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When dealing with complex disorders such as autism where the epistemology of the disorder (i.e. 
the nature and way in which it may be regarded as genetic) is not well-understood, much 
controversy exists amongst researchers and further differences may arise concerning the validity 
of research findings (Miller et al., 2010). Miller and colleagues (2010) suggest that in order to 
honour research participants’ desires for meaningful results information, a few things need to 
happen. 1) Studies will have to ‘contend’ over time in order to establish or contest the true nature 
or etiology of disease, 2) researchers will need to remain clear and transparent regarding their 
disagreements, and 3) research participants will need to be engaged at a level of meaning of 
results and what kind of results they would like to receive, at the level of validity of results as well 
as the level of epistemology (Miller et al., 2010).   
 
Currently, there has been limited research and no publications conducted in SA on this topic to 
date that the researcher is aware of. This study serves to be a first of its kind locally. 
 
2.2.2 CHILD’S AUTONOMY 
 
Research involving children has the potential to hold benefit for everyone since many adult-onset 
as well as complex diseases/disorders have their antecedents in childhood. However, a 
fundamental difference in paediatric compared to adult research is the inclusion of a third party 
into the decision-making/consent process for the return of genetic research results, namely the 
parent. This parent-child-researcher triangulation adds complexity to the research process, 
especially with the need to consider the child’s evolving capacity to make decisions that reflect 
the child’s preferences regarding the RoR. 
 
Ethical frameworks for the RoR in children have been proposed by a few (Avard, Denise et al., 
2011; Holm, 2017; Holm et al., 2014; Knoppers, 2014); and the Presidential Commission for the 
Study of Bioethical Issues (2013) states that policy and options for this purpose be clearly outlined 





Important ethical principles which arise during the consideration of  returning  genomic information 
include that of beneficence (acting in a person’s best interests) and autonomy (respect for persons 
and their right to self-determination), both of which can be complex when it comes to decision-
making regarding children, particularly vulnerable groups such as those with NDDs. Researchers 
have a duty to act in the best interests of the research participant and must uphold professional 
standards; parents have a duty to make decisions that are in the best interests of their child and 
they have the authority to do so; children have an evolving capacity 1) to make decisions for 
themselves, 2) for autonomy given that they will have full autonomy as future adults. The child 
has a right to an open future and parents have a duty to preserve that opportunity in a manner of 
decision-making on behalf of the child that will afford the child the opportunity to make his/her 
own decisions as adults. Adding to possible conflict, beneficence and autonomy are person-
dependent in that the parent has a view of what is in the best interests of their child and 
themselves and they have the autonomy and authority to make these decisions for their child; the 
researcher’s view is to protect the best interests of the child and family and to uphold professional 
standards and obligations to their research; and the child has a growing and future autonomy 
(Holm, 2017). Even more so, research has the ability to contribute to the greater good of the 
community. This is to say, doing the research may help a group of people in determining causal 
pathways, best treatments and so forth, though it may not necessarily be beneficial to the 
individual family who is involved in the research process. 
 
During the consent process, a clear explanation of the policy and procedures of the research 
being conducted should be provided, and if return of research results is feasible, should give 
participants the option of receiving their results and should consider their preferences regarding 
the types of results they would want to receive (Holm, 2017; Kohane & Taylor, 2010; Sapp et al., 
2014; Ziniel et al., 2014). In other words, participant choices are made during this time of consent, 
however, in paediatric research, the parents of the child provide “proxy” consent and the child 
participates through an assenting process fit for his/her age-appropriate capacity but engaging 
the child participant as much as possible in the research process is an important aspect. During 
the consent/assent process, explaining to the family where and what choices they may have, that 
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results for highly actionable childhood onset conditions will be returned and results for non-
treatable adult-onset conditions will not be returned, may result in a truly informed consent 
process and overcome many ethical challenges.  Prior to consenting to participation, individuals 
should be made aware that their preferences may be set aside in certain instances (Holm et al., 
2014). 
 
Consensus seems to be that only certain results – namely, those likely to be acutely important for 
the health of the child before adulthood - should be offered to the parents and their families under 
certain conditions (IRCM Working Group, September 2015). Results of an adult-onset or carrier 
status nature are generally not revealed and only results that are actionable are disclosed at the 




Issues of blame may arise in the event that a research discovery reveals causative mutations 
which appear to be inherited from one parent. These mutations are passed down from the parental 
lineage to the offspring, who is then a carrier of the same mutation and who is then also at risk of 
passing the mutation on to her children in the same manner. In such situations, it may be easy to 
assign blame to the partner for passing the condition on to the child. Amidst this blame, feelings 
of guilt or shame may also ensue as the individual may deem themselves as ‘broken’ or unfit to 
reproduce or blame themselves for their child’s condition. In certain cultures these feelings may 
even be exaggerated by a partner choosing to take a new partner in order to have more, 
unaffected children. The psychological well-being of the research participants should always be 
in the forefront of a researcher’s responsibility and it is thus of utmost importance to clarify the 
preference of participants when partaking in research as to which results they would want to 







2.3 INTERNATIONAL GUIDELINES AND SA-SPECIFIC GUIDELINES 
 
General guidelines for the return of genomic research results traditionally focused on analytic 
validity, clinical validity, actionability and severity of the outcome (i.e. the nature of the result itself), 
however, studies have shown that parents of paediatric participants often desire to receive all 
research results, regardless of clinical utility or actionability, and indeed they do have a right to 
know information that may be important to their child’s medical care (Harris, et al., 2012; Holm et 
al., 2014). 
Albeit wide variability regarding the return of individual research results, several international 
policies recommend that the return of IF be obligatorily disclosed when relevant to health or quality 
of life (IRCM Working Group, September 2015). 
 
2.3.1 INTERNATIONAL GUIDELINES 
 
The American College of Medical Genetics (ACMG) and 100,000 Genomes Project (UK10K) 
guidelines stipulate that pertinent findings directly related to the cause of the condition must be 
fed back to participants and consent obtained from the participants as a prerequisite for 
participation in the study. They further state that secondary findings that fall within their list of 
recommended genes meeting their threshold of clinical significance be returned to participants. 
The ACMG list comprises of 59 recommended genes and includes IF (Green et al., 2013), 
whereas the UK10K has a more limited list of secondary findings of high clinical relevance to 
which the participant may have the option of opting out from receiving, however, IF will not be 
returned (Mark et al., 2017). 
 
Other policies take participant preferences into account: 
World Health Organization (WHO) guidelines and The Canadian Tri-Council Policy Statement 
(2018) stipulate that ‘disclosure be made on the basis of a clear demonstration of clinical benefit 
and communicated in a way that averts or minimizes harm so long as there is evidence that the 
individual would prefer to know’ (Canadian Institutes of Health Research, Natural Sciences and 
Engineering Research Council of Canada, and Social Sciences and Humanities Research 




According to The Network of Applied Genetic Medicine international research ethics guidance for 
policies and practices relevant to children, ways in which researchers acknowledge and balance 
the rights of parents and children not to know about genetic findings should be included. These 
include ‘respecting parents and children when they indicate not wanting to know about results; 
overriding preferences not to know when the results have significant health implications for the 
child; and extending the right not to know to relatives’ (Avard  et al., 2012). These guidelines leave 
room for the RoR to be an option rather than an obligation according to Lévesque, Joly & Simard 
(2011). 
 
2.3.2 SOUTH AFRICA 
 
H3Africa guidelines state that findings that are pertinent to the original research project will be 
returned to participants once the evidence base (analytic validity and validation by a certified 
diagnostic laboratory) has been assessed for potentially pathogenic variants in relation to the 
population being investigated, the value of the finding to the participant has been assessed, and 
participants have been appropriately informed of the implications of the findings for disease and 
treatment and follow-up care has been established (Rotimi et al., 2014). 
 
However, SA and Africa as a whole, is lacking in legal and ethical guidelines/policies relating to 
the feedback of genomic research results, and ethical challenges are compounded by low literacy, 
poverty and socio-economic barriers (Masiye, Mayosi & de Vries, 2017). Gornick et al. (2017) 
found that research participants in the U.S. were less concerned about which policies were in 
place regarding the return of IF than they were about having the choice to decide which findings 
they wanted to receive. SA is a country that places high value on choice, which needs to be 
considered in ensuring harmony between research participants and researchers, before setting 
up any guidelines and policies. Participants need to be educated on possible research findings 
and their implications before consenting to participate in the research (Gornick et al., 2017). Public 
opinion, participant preferences and tailored FoF is pivotal to the success of the feedback 
process, especially in SA due to our cultural/demographic and linguistic diversity. The lack of such 





2.4 NEURODEVELOPMENTAL DISORDERS (NDDS) 
 
2.4.1 WHAT ARE THEY 
 
NDDs are a group of complex disorders characterised by developmental deficits such as impaired 
functioning on a social, personal, academic or occupational level. These disorders typically 
manifest in early development and according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-V), can include disorders like autism spectrum disorders (ASD), attention-deficit 
hyperactivity disorders (ADHD), intellectual disability (ID), global developmental delay (GDD), 
communication disorders and specific learning disorders (e.g. dyslexia) (American Psychiatric 
Association [APA], 2013). There is considerable co-morbidity between some of the disorders, 
which complicates the process of determining the burden of these conditions. 
 
2.4.2 BURDEN IN SA 
 
There is an overall lack of recent population-based data on NDD prevalence in SA. The only SA 
data emanates from a study conducted in a rural region of Mpumalanga (Bushbuckridge) where 
researchers diagnosed 3.56% of the children they examined with ID (Christianson et al., 2002). 
A study conducted in Uganda found the prevalence of NDDs to be 12.7% (Namazzi et al., 2019). 
To put this into perspective, the reported global prevalence of NDDs is 8.4% (Olusanya et al., 
2018), and Bitta et al. (2017) conducted a systematic review of reported prevalence and incidence 
of NDD, determining a minimum-pooled prevalence of 7.5 per 1000. 
Other than the co-morbidity between some NDDs, reasons for complicating burden estimation 
also include 1) the age of the child, because some NDD only manifest later in life and tools used 
to detect these disorders may not be sensitive enough at such a young age; and 2) difficulties in 
diagnosing most NDDs, especially those which affect intellectual compared to physical functioning 





2.4.3 GENETICS AND NDDS 
 
NDDs are a group of complex disorders and can exist alone or be syndrome-related. A 
considerable proportion of NDDs – about 15-20% (Urban, 2015) – are due to small 
deletions/duplications that can typically be detected by microarray testing with the diagnostic yield 
increasing by 12-30% amongst those 40-60% of cases where the diagnosis remains unclear using 
conventional karyotyping, which only detects 3-5% (Rawal, 2019, Xu et al., 2018). 
There are some variants that have been associated with ASDs and internationally-based 
diagnostic panels for testing do exist. However, due to the complexities of NDDs it is generally 
difficult to pinpoint specific variants as a single underlying cause for these conditions and 
individual variants may not necessarily be pathogenic in themselves as is the case in monogenic 
disorders. This is due to considerable overlap with individual phenotype, interaction with other 
variants, as well as gene-environment interactions that may contribute to the development of the 
disorder. A particular challenge is that many of the variations associated with NDDs appear to be 
de novo significant variants rather than familial in origin. The findings from studies such as the 
NeuroDev study may hence be difficult to interpret and not necessarily identify single mutations 
explaining the genetic cause. 
 
Greater understanding is needed of the genetic contribution of NDD causation in Africa, as well 
as the gene-environment interactions and their resultant expressivity or phenotypic effects in 
individuals. This may assist in developing better diagnostic, treatment and management tools in 
Africa. Another requirement is to increase community education regarding these conditions (de 









2.4.4 CURRENT CLINICAL PRACTICE IN GENETIC TESTING FOR NDDS 
 
Technologies employed to test for NDDs and the availability of skilled health professionals to 
analyze and interpret findings is abundant and cost-effective internationally. However, SA faces 
many challenges and inequities related to being a third world country and as such, the practise of 
genomics and genetic testing is influenced by an overall lack of resources, whether it be of skilled 
health professionals or equipment, infrastructure or financial limitations. 
In certain public clinical settings in the WC, current methods often employed for the diagnosis of 
NDDs are microarray and multiplex-ligation probe amplification (MLPA) analysis, nonetheless, 
due to resource constraints, these are not always routinely available for all patients (Urban, 2015) 
and NGS is used sparingly; restricted access to such testing may particularly occur in the public 
sector where use needs to be made of external laboratories for testing, resources are limited and 
the health sector is overburdened. 
 
2.5 THE NEURODEV STUDY 
 
The NeuroDev study is a large-scale, international collaborative study which aims to contribute to 
mapping the genetic variation amongst children with NDDs in Africa by performing genotyping 
and exome sequencing on children, aged 2 – 17 years old, with NDDs in SA and Kenya. 
Genotyping will allow for differences in the genetic make-up of an individual to be determined by 
comparing the individual’s DNA sequence to a reference sequence (control group), thereby 
revealing the alleles the individual has inherited from their parents. Current study sites are located 
in SA where 1,100 children will be recruited in the WC and will be matched against ancestral and 
geographically similar case controls. The study aims to phenotype these children 
comprehensively and to perform genetic testing via exome sequencing of both affected children 
and one or both parents where available. Expected findings include de novo significant variants, 
meaning that they will be relevant to the child’s clinical condition. If the study identifies common, 
known genetic causes of NDDs, then researchers will take a second sample for confirmatory 
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diagnostic testing. Positive results (clinically confirmed by microarray testing for known genetic 
diagnosis of NDDs) will be fed back to individual research participants or their parents. 
 
2.5.1 THE NEURODEV FEEDBACK POLICY 
 
2.5.1.1 THE POLICY 
 
The NeuroDev study requires consent from the parents and assent from the child (where 
appropriate)  for the child to participate in the study. Parents also need to consent to their own 
personal participation should they wish to participate whereupon personal refusal will not hinder 
the child’s ability to participate in the research. 
 
The feedback of results process will involve re-contacting the participant after identifying a genetic 
variant at research level sequencing which may potentially be causative of the child’s condition. 
At this time, they will be reconsented, a new blood/saliva sample will be taken and confirmatory 
clinical sequencing will be performed at a Clinical Laboratory Improvement Amendments (CLIA)-
certified laboratory in the U.S. to confirm the finding and whether it meets criteria for returning to 
the participant. 
 
The NeuroDev study will only be returning primary research findings of variants in known 
pathogenic genes that have been associated with ID or ASD. At variant-level, pathogenicity will 
be determined by following the ACMG, Association for Molecular Pathology (AMP) and College 
of American Pathologists (CAP) guidelines to classify the variant’s role in disease. The parents of 
participants in this larger study are informed at the time of consent for participation that they may 
not receive any clinically meaningful results from this study and of the possibility that no results 
may be generated. No adult-onset conditions but only findings relevant to the child’s clinical 
condition which are the primary focus of the study will be returned, and no IF will be returned due 





2.5.1.2 SPECIFIC NDD CONDITIONS BEING TESTED 
 
Structured according to the DSM-V, the group of NDDs being tested within the NeuroDev study 
will include ID, GDD, communication disorders, ASD, ADHD, and specific learning disorders (e.g. 
dyslexia) with the exclusion of Cerebral Palsy (CP) and motor disorders. 
 
2.5.1.3 QUESTIONS OUTSTANDING FOR NEURODEV TO INFORM APPROPRIATE 
FEEDBACK 
 
1) Why do people consent to receiving results? 
2) What do they expect from the results? 
3) How best to return these results? 
 




Previously, I described that there is little empirical evidence in SA about FoF. I also described that 
there is no current practice for returning results from research studies. Against that background, 
I described that the NeuroDev project has a very detailed feedback policy that is already being 
implemented. In that study, participants are already consented to receive results when they enroll 
in the study. However, a key question remains as to participant expectations and how to feedback 
results. There is an opportunity for GCs to impact on this field but before this is implemented, it is 
important to know more about what participants understand regarding the genomic studies in 
which they participate and consent processes through which they may have been taken, their 
understanding of the impact of results and uncertainty which may arise as a result, understanding 
of scientific terms, personal meaning of results, as well as what they expect in return for 
participating in such genomic studies. Therefore, this study specifically set out to investigate 





Africa is the cradle of humankind and serves to be a valuable resource of genetic information in 
terms of its immensely diverse population, however, limited knowledge exists on African-specific 
variants (Campbell & Tishkoff, 2008). Furthermore, between 2000 – 3000 languages are spoken 
here (de Vries et al., 2013), and difficulties in explaining scientific methods and concepts in local 
languages have been described frequently (Masiye, Mayosi & de Vries, 2017). These dynamics 
make the nature of potential services challenging; however, with expanding knowledge and 
understanding of complex disorders generated by genomic studies such as the large-scale 
studies being conducted on NDDs in Africa namely, NeuroDev and the Deciphering 
Developmental Disorders (DDD) project in Johannesburg, it is pertinent to ensure that our method 
of communicating complex results (which may not necessarily translate into a single mutation 
explaining the genetic cause) is conducted in a comprehensible and harmless manner. 
 
Against this backdrop, we proposed to conduct a study pertaining to the manner in which 
sensitive, pertinent, genomic research results derived from a SA NDD paediatric cohort may be 
communicated to this diverse population in a way that is demographically and linguistically 
appropriate, comprehensible, culturally respectful, empowering, and dignified. This study set out 
to specifically explore how these pertinent, individual results relating to NDD causation can best 
be fed back in the SA context. The approach was to engage with enrolled participants to explore 
how this component of the study was explained and understood, and what patient preferences 
were for the RoR . 
 
2.6.2 SPECIFIC AIMS 
 
This project aimed to investigate parents’ understanding of the NeuroDev study and preferences 
regarding the feedback process of genomic research results obtained during the NeuroDev study 
and the anticipated contributions of such findings. Results from this study may inform a return 
policy for pertinent genomic research results for the NeuroDev study which is demographic-
appropriate, sensitive and tailored to the SA population and could possibly be of wider use to 
other genomic research being conducted at UCT. 
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2.6.3 STUDY QUESTIONS 
 
To determine: 
1. What do NeuroDev research participants consenting to the return of positive individual 
NDD-related genetic results understand from the study to which they have consented? 
2. What reasons NeuroDev participants give for their decision to agree to the return of 
positive individual NDD-related genetic results? 
3. Recommendations for how positive NDD-related individual genetic research results can 








The previous chapter outlined the current literature available on current policies/guidelines 
concerning genomic research and participant preferences regarding the return of individual 
results. It serves as a background to this study and describes how feedback of genomic research 
results may be successfully implemented by adhering to ethical guidelines for informed consent 
and considering participant perspectives and preferences. It also introduced the NeuroDev study, 
outlines the rationale for the current study and introduced the aims. This chapter describes the 
methodological framework employed to conduct this study, participant recruitment and sampling, 
an explanation of the research procedure, data collection and analysis as well as ethical 
considerations undertaken. 
 
3.1 STUDY DESIGN 
 
This study was conducted using a pragmatic qualitative approach, which allows a researcher to 
study the lived experiences of individuals and to derive in-depth, descriptive information from 
study participants (Savin-Baden & Major, 2013). A pragmatic approach provides descriptive 
information and believes that the worldviews and perspectives of research participants, 
phenomena and processes can be understood by careful qualitative interrogation (Savin-Baden 
& Major, 2013). Qualitative research seeks to understand human behaviour. According to Kumar 
(2014), it is a ‘holistic approach built around the premise that as a multiplicity of factors interact in 
our lives, we cannot understand a phenomenon from just one or two perspectives’. In order to 
understand a situation or phenomenon, it needs to be looked at it in its totality and from every 
perspective, i.e. holistically (Kumar, 2014). It holds the view that reality can be interpreted in 
multiple ways and that the goal of research is to understand how individuals construct reality 
within their natural context. A ‘thick description’ of these contexts will render their behaviour, 
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experiences, perceptions and feelings meaningful and will allow for transferability (Korstjens & 
Moser, 2017). Due to the limited amount of research conducted on this topic in SA, a qualitative 
research approach appeared best suited to unpack parental preferences regarding the return of 
research results, since such an approach can pay equal attention to rare or complex phenomena 
and allow an insider point of view as experienced by the participant. In addition, quantity does not 
bear weight of importance but rather, the focus is on painting a wider picture (landscaping) to 
investigate concepts such as emotions, understanding or preferences which are hard to measure 




This project was specifically interested in determining the preferences of existing research 
participants to the return of individual causative genomic results to inform a feedback policy for 
the NeuroDev study, a large-scale genomic research study in which participants have already 
consented to receive pertinent results. 
Therefore this study made use of purposive sampling to recruit parents of children who 
participated in the NeuroDev study. NeuroDev staff pre-screened their participant recruitment 
database for those willing to be re-contacted for secondary research and gave a list of participants 
that could be contacted for this study. 
 
Inclusion criteria for participating in this sub-study were: 
1) Biological parent or primary caregiver of a participant in the NeuroDev study 
2) Cognitive capacity to consent, as assessed in the NeuroDev study procedure 
3) Parents/caregivers consenting to be contacted for further research 
No minor assent was required for this sub-study since it only focused on parental perspectives 








Participants were selected based on the study purpose to provide unique and rich information of 
value to the study. As such, participants were recruited from the NeuroDev study cohort who 
were well-informed about the NeuroDev study’s return of results policy and were thus able to 
provide information regarding their preferences for the return of their child’s genomic research 
results. These participants were available, willing to participate, and able to communicate their 
experiences and opinions. The limitations of such non-random (i.e. purposive) sampling is that 
the researcher is subjective and bias in selecting participants for the study and gathered 
information cannot be generalized to the larger population (Etikan, Musa & Alkassim; 2016). 
However, the researcher’s aim was to achieve a greater understanding of the preferences to the 
return of results of parents whose children are enrolled in a genomic research study as opposed 
to a breadth of understanding regarding public preferences.  
The NeuroDev study retains the contact details of all participants within its cohort. The researcher 
of this study provided a list of criteria (mentioned above) for participants that she wanted to 
interview for this study and based on these criteria, the NeuroDev PI/study staff provided the 
researcher with a selection of people within the NeuroDev study eligible to participate in this study. 
This list comprised of 20 prospective families eligible for recruitment, who had been asked if they 
were willing to be contacted about further research by the PI/study staff working on the NeuroDev 
study at the time of recruitment into the NeuroDev study. Those who had consented to be 
contacted were approached telephonically by the researcher of this study and informed about the 
aims and objectives of this sub-study. For those who then gave verbal permission to participate, 
a date and time for the in-person interview was set up telephonically, via WhatsApp, text message 
or email. Of these 20 families, 13 families were contacted, 12 families consented to participation 









3.4 RESEARCH PROCEDURE & DATA COLLECTION 
 
Twelve in-depth, semi-structured interviews were conducted in English at a time convenient to 
participants and took place in private rooms at RCWMCH. 
 
The interview guide was structured around the following themes: participant understanding of the 
genetic research study they are participating in, their reasons for participating and their preference 
for the FoF. The themes were identified based on the literature review, examining previously 
developed guides from similar research conducted in other settings and questions were adapted 
to suit our setting, aligning them with this study’s objectives. Keyword prompts/phrases were used 
to guide the researcher and to allow for adaptation into relevant open-ended questions during the 
interview process, allowing for flexibility (Korstjens & Moser, 2017; Korstjens & Moser, 2018). Test 
interviews were conducted with three GC students to explore the utility and structure of the 
interview guide. Following revision the interview guide was piloted with two NeuroDev participants 
before final revision and implementation. Given the quality of the pilot interviews, these pilot 
interviews were analyzed together with the main data. A final interview guide can be found in 
Appendix A. 
 
Interviews lasted for approximately one hour and were audio-recorded. Throughout the face-to-
face interviews, shorthand notes were recorded and field notes written immediately following 
interviews to capture any elements and observations relevant to the research and data analysis. 
Field notes assisted the researcher in the process of recording and analyzing and proved an 
essential opportunity for reflection and data contextualization. On the same day, following the 
interviews, the researcher listened to the recordings and captured any observations and 
emerging insights in the field notes. These were then integrated into subsequent interviews. By 
interview ten, similar concepts and themes arose in the interview data which led the researcher 
to believe that data saturation may have been reached. This was tested by interviewing one 
more parent with a child with an undiagnosed condition and one more couple with a child 





Transcription was done by a dedicated transcription company. Recordings were transcribed 
verbatim and the researcher listened to recordings to check the accuracy of transcriptions. Field 
notes taken during the interviews provided a summary of the interviews and informed transcripts. 
Transcripts were imported into NVivo 12 (QSR International data analysis software) to assist with 
managing and organizing the data for analysis. 
 
3.5 DATA ANALYSIS 
 
Interview data and observational notes were analyzed using thematic analysis and framework 
matrices. Themes were extracted from the data, a process which commenced immediately 
following transcription of initial interviews. Thematic analysis assisted the researcher in 
understanding the meaning the participants were communicating (Kumar, 2014). Through using 
framework analysis, robustness and rigour was attained by allowing for clear audit trails of cases 
and for others to be able to follow the researcher’s process (Gale et al., 2013). Framework 
analysis organizes and reduces the large amounts of data in qualitative research and allows for 
better understanding of participant perceptions and experiences by enabling the researcher to be 
fully immersed in the data (Gale et al., 2013; Hackett & Strickland, 2019). This was achieved by 
manually analyzing the first three interview transcripts through use of an open coding strategy 
which assigned open codes to relevant or interesting text excerpts. These codes were descriptive 
of the content of the quotes and were checked by one project supervisor to ensure reliability of 
code application over transcripts. Drawing on the list of open codes, a mind map was compiled 
with preliminary themes and both themes and coded text was imported into Excel and there re-
organized into sub-themes/categories. In this way a hierarchical coding scheme was developed. 
The hierarchical coding scheme was reviewed by two of the project supervisors independently. 
In addition, one of the supervisors also used the hierarchical coding scheme in one transcript to 
ensure that it covered the data appropriately. Following that, all the coding was done by one 
individual and as such, the issue of inter-coder reliability was not of concern. Following this, the 
transcripts were then imported into a new NVivo 12 (QSR International data analysis software) 
project and the pre-determined code-set was applied in the software. Using the coded dataset, 
data summaries were generated using the framework matrice option in NVivo 12. Emerging 





The researcher incorporated quotes from research participants into text excerpts which assisted 
with providing thick descriptions and context of participant meaning and experiences.  To ensure 
credibility, the original data drawn from participant responses were incorporated to represent the 
correct interpretation of participants’ views (Korstjens & Moser, 2018). 
 
3.6 ETHICAL CONSIDERATIONS 
 
Information sheets and consent forms were explained and read to participants on the day of the 
interview to ensure that they were fully informed. Only one participant received the forms via email 
but forms were read through and signatures obtained on the day of face-to-face interview. 
 
Respect for the individual, the individual’s right to autonomy and their right to make informed 
decisions with regards to participating in research are fundamental principles for medical research 
involving human subjects (CIOMS, 2016; Declaration of Helsinski, 2014). The researcher has to 
be cognisant of the fact that ‘the subject's well-being should always take priority over the interests 
of science and society and ethical considerations must always take priority over laws and 
regulations’ (General Assembly of the World Medical Association [WMA], 2014). Ethical approval 
for this study was obtained from the UCT HREC (HREC 784/2018) as well as Institutional approval 
from RCWMCH. 
 
3.6.1 INFORMED CONSENT 
 
Research participants were informed verbally and in writing (see Appendix B) about their 
enrollment in this qualitative sub-study and written consent was obtained in English (see Appendix 
C). Participants were informed that their participation in the study was completely voluntary and 
that they were able to withdraw from the study at any given time should they wish to do so, without 
consequences to their current and future medical care. 
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Prior to obtaining written consent, participants were informed that a suitable translator previously 
used by UCT Department of Human Genetics could be made available, should they experience 
a language barrier, to ensure participant understanding of the information. All participants felt 
comfortable conducting the interview in English and none requested the translator to be present 
during the consent process and interview. All participants received a copy of the information form 
and the researcher kept the signed forms for her records. 
 
3.6.2 PRIVACY AND CONFIDENTIALITY 
 
Participants were advised that interviews would be audio-recorded and transcribed. They were 
informed that a code would be assigned and that names and any identifying information would 
not appear in the data. The researcher would be the only one with access to their personal 
information. Participants were informed that all audio recordings and written data obtained from 
the study would be locked away in a cupboard or stored on a password-protected computer. They 
were informed that upon completion of the research, hard copies of data will be shredded and 
disposed of. 
 
The participants were advised that the data obtained during the research process would only be 
made available to the researcher and supervisors directly involved in the study and will be written 
up in a dissertation and possibly a publication, without any identifying information. They were also 
informed that all the information obtained will remain confidential and will be used for the sole 










3.6.3 RISKS AND BENEFITS TO PARTICIPANTS 
 
There were no identified direct risks associated with the interview process for this study. During 
the consent process, the participant(s) were informed that they had the option to opt out of the 
study at any given time should they feel uncomfortable with continuing. 
 
Given the sensitive and personal nature of the information, some emotional difficulties were 
experienced during the interviews. The participants were given the option to refrain from 
answering certain questions or even withdraw from the study if they felt upset or unable to 
continue and designated support and/or counselling would be assigned to the participant if 
needed. One participant was flagged due to concerns over extreme emotional difficulty caused 
by her circumstances and difficulty coping with her child’s condition. A psychology referral was 
offered to the participant but she declined the offer. Following discussion with supervisors, it was 
decided not to follow-up for now. 
 
Benefits of this study included that participants were able to share their stories and make sense 
of their child’s condition. Storytelling is seen to have therapeutic benefits and has allowed for 
groups of individuals, with similar conditions or situations, to be heard (Koch, 1998). Some 
participants did seem to experience therapeutic benefit and thanked the researcher for “just 
listening” to their story. Another potential benefit is increased awareness amongst participants of 
the research being conducted and of what to expect from the NeuroDev study since the 
researcher offered to answer questions participants may have following the interviews.  
 
Participants were offered compensation for their time and travel expenses to the value of R100 – 
R250 in keeping with compensation offered in the parent NeuroDev study. 
 
Information obtained during the interview process may aid in improving our understanding of 
participant preferences and experiences regarding the return of their child’s genomic result, as 
well as the underlying beliefs and attitudes that shape these preferences. This information is 
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beneficial for health care practitioners, including GCs, to understand and assess the efficacy of 
currently employed feedback methods and to establish more effective, preference-based 
methods which will guide healthcare professionals during the feedback process and minimize the 




This research project focuses on the perspectives and preferences of parents whose children are 
recruited into a genomic research study regarding the feedback of individual pertinent results. 
This chapter has provided insight into the methods employed to conduct this study that would 
help achieve the aims of this study. The next three chapters will focus on the results of this 
analysis, categorizing it into three sections, namely participant understanding, expectations and 
reasons for partaking in genomic research, their reasons for wanting/consenting to the return of 




4 CHAPTER 4 RESULTS –  PARTICIPANT UNDERSTANDING, EXPECTATIONS & 




In ‘Chapter 3’ I described the study methods and research objectives. In this  chapter I start with 
a  brief summary of participant sociodemographic information then explore the broad context of 
what participants want to know, their reasons for participating in genomic research, as well as 
desired outcomes from genomic research, aiming to address the research question regarding 













4.1 SOCIODEMOGRAPHIC DATA 
 





A total of seventeen participants were recruited, of which twelve were female. Seven individual 
and five couple interviews were conducted with the parents of children enrolled in the NeuroDev 
study. Of these, fifteen parents had a child diagnosed with autism whilst two parents had a child 
with an undiagnosed NDD-related condition. All participants were from Mixed Ancestry and the 
Xhosa ethnic groups reflecting the demographic of the patient population of the hospital. 










4.2 THEME 1 | PEOPLE WANT TO KNOW 
 
As described in section 2.5.1.1, the NeuroDev policy is to return pertinent results only. However, 
it is evident from this study that participants want to be informed of findings that have preventable 
implications for their child’s health. Such findings may be inclusive of all results which are 
medically actionable and have clinical utility, whether it be pertinent results or incidental findings. 
 
P16: “Yes. Like I mean, if they found something that is, like I’ve said, of importance, they found 
that he has something that could be treatable, or that if we leave it it’s going to cause harm or 
whatever, then yes, I would expect them to come back to us and let us know.” 
 
This desire is consistent with evolving consensus in ethics literature around RoR which seems to 
indicate that individual genetic findings be returned to participants if they are 1) medically 
actionable or have clinical utility, 2) can be associated with disease causation, and 3) can offer a 
diagnosis which may not have been made without such a finding (de Vries & Munung, 2019; 
Eckstein, Garrett & Berkman, 2014). 
 
4.3 THEME 2 | REASONS TO PARTICIPATE IN/SUPPORT GENOMIC RESEARCH 
 
Altruism and personal/family benefit seem to be the primary reasons individuals decide to 
participate in genomic research overall. In the section below, I elaborate on each of these two 












Altruism was a major motivator for most of the research participants interviewed for this study 
who described that they participated in NeuroDev because it could ‘help others’. For instance, 
 
P8: “So that once they find out what the cause is of it, it can help many other parents that struggle 
to accept their children’s diagnosis. Before he was diagnosed, I was already told that it could be 
that. And I accepted it. When he got diagnosed, I cried, and then I just spoke up and told myself 
that he’s still my child. Nothing is going to change. And from there onwards I’ve been doing so 
much to help other parents. I’ve created my own WhatsApp group and we have a support group 
and when it’s awareness stuff we participate in it…Because I know my husband in the beginning 
was in denial and I know how hard it is to do it, accept it only on your own.” 
 
Specifically, participants expressed that they hoped the research could motivate institutions to 
increase access to resources. 
 
P17: I’d like to do more, I mean, I’d like to do more for other people...I’d like to see that research 
motivating government, the health department. I hope that’s going to happen…After the research, 
I mean, that for me, that there’s more support for people that just don’t have the resources to do 
anything. 
 
Previous studies conducted have also identified altruism to be a motivating factor for participating 
in research, defining it as a ‘prosocial behavior’ which includes a desire to help others or to 
advance research in genetics or health (Facio et al., 2011; Gollust et al., 2012; Halverson, Clift & 






When interviewed for this study, participants expressed their desire to help other families accept 
the condition by increasing support and offering a place of belonging for those experiencing 
difficulties in coping with a child with Neuro-Developmental abnormalities but they also hoped that 
information gathered through research would lead to prevention of these conditions in future. 
Unexpectedly, many of the interview participants indicated that one of the unforeseen side-effects 
of participation in the NeuroDev study was that they met other parents of children with NDD 
conditions. Because many of the interview participants struggled to cope with their children and 
indicated feeling isolated, meeting other parents facing similar challenges was really important. 
After meeting, participants described that they had exchanged numbers, started their own support 
groups and were trying to raise awareness in their communities. This concept of finding comfort 
through connections and self-advocacy was also noted by Halverson, Clift & McCormick (2016). 
 
P15: “To be honest with you, when I started this I knew it wasn’t about her. It was basically about 
future children and helping future children not to be … not, not to be, but to just eliminate the 
amount of these types of abnormalities, basically. And also to gather a way of actually having a 
support for parents who do have children this way. Because I was one of a few until I came to 
NeuroDev for example, and I actually got to meet other parents. Not the same type of eye 
disorder, but also visually impaired. So it’s a lonely journey until you find a community that shares 
the same. So that’s the only thing that was very hard in the beginning. It’s not knowing anybody 
that also understands or has a similar idea of what you are experiencing.” 
 
Importantly, for some participants altruistic intentions were more important than the possibility that 
they could receive some genetic results. These individuals felt that having a result would not 
change anything and were determined not to ‘dwell in the past’ with questions of ‘where’ and 
‘what’. 
 
“P8: “I’m not really worried even. I’m not. Like I said, I partook in it so that it can help many other 
people. For me on my level that I am at now I fully accept it like it is. There are tough days, there’s 
going to be that. But like for me I’m not worried if it’s me, if it’s my husband, whoever is the cause 
of it, where it comes in the genetics.” 
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4.3.2 PARTICIPATING FOR PERSONAL OR FAMILY BENEFIT  
 
Alongside altruism, and as noted in various studies (Allen et al., 2014; Biesecker et al., 2009; 
Kauffman et al., 2017; Sanderson et al., 2016), personal and family benefits were also strong 
motivators for participating in the NeuroDev study.  Individuals expressed hope that genetic 
results could help reduce risks of developing a condition or identify ways to prevent them from 
happening. They also indicated that they hope results may help them prepare or plan for the future 
(Scherr et al., 2018). In this study, some participants felt that recognizing the condition or 
becoming aware of genetic status earlier may increase intervention for those affected individuals 
and/or their families and possibly prevent these conditions from occurring in others. Interestingly, 
participants also described that they were motivated to participate in the NeuroDev study in the 
hope of finding a cure/treatment, despite simultaneously describing that they knew that this is not 
what the study set out to do. 
 
P7: “You see, there’s many … I don’t know if I can make it, like condition, there’s many conditions 
out there and people who don’t know about it, and others know, but others they don’t care. And 
sometimes you’ll find if they could have found it earlier maybe by now there is supposed to be a 
cure for it. Or there could’ve been something that they can do to help those people who suffer 













4.4 THEME 3 | EXPECTATIONS ABOUT THE IMPACT OF THE NEURODEV 
RESEARCH STUDY & GENERAL STUDY RESULTS 
 
Some of the results discussed in this section show some overlap with what people expect 
individual (not generic) study results to illustrate. For this study, it was sometimes difficult to 
disentangle these as concepts. For example, the participants’ need  for information served 
multiple purposes on an individual and broader level for some individuals. This included that the 
information could help with management of their child and lead to self-empowerment, it could 
assist with gaining some form of acceptance of their child’s condition through diagnostic closure, 
and help reducing the recurrence of these conditions.  
Participants felt that the study could offer them the opportunity to give their child the best chance 
in life with a more favourable outcome and could potentially fulfill their need for information. They 
hoped that results could help establish the course of the condition and options for treatment. 
 
4.4.1 BEST CHANCE IN LIFE 
 
Overlapping with altruistic motivations for research participation, interviewees expressed the hope 
that results could educate and help people understand and recognize the signs of ASD, thereby 
enabling the diagnostic process for other children. 
 
P13: It will teach us something, like if you see … because we didn’t know that … the first we know 
that he has autism it was 2017. Because since when he was young we didn’t know that he has 
got autism. So if we got the result and then they explain us, maybe lead us to the grain of this we 
know that the signs of this if you see something like this, we know, oh, they teach us that autism 
children are like that, like that, and like that. So it will help us to understand and then to know if 





Expectations varied from finding a cure for autism (as mentioned previously) to wanting an 
improved outcome for their child, with the opportunity of giving their child the best chance in life. 
This referred also to means of helping their child interact with others and acquiring developmental 
and social skills. 
 
Some parents desired broader outcomes from general study results, describing that they were 
less interested in receiving a positive result and more interested in results that could help them 
understand their child’s prognosis and how best to support them. 
 
P9: “I would like something positive, but if not, I’ll accept anything that’s coming out of that. I know 
he’s been diagnosed with autism. So it’s not like it’s going to just disappear overnight. I know that 
there’s no medication also that can cure it. So it’s something that we need to live with. It’s just I 
would say that to better our situation.” 
 
Participants hoped that the NeuroDev study could offer them the opportunity to learn more about 
their child’s condition and to support them by providing the best chance in life for their child by 
being a means of support on their journey, emphasizing the need that research participants have 
for information and support. 
 
4.4.2 ESTABLISHING CERTAINTY 
 
Many participants seemed to express the need to establish certainty amidst all the unknown 
factors associated with NDD disorders and long-term prospects. They hoped to reduce 







P5: “it’s very difficult for me with handling him at home. It’s very difficult. So he gets occupational 
therapy and he gets speech therapy…But the last appointment that I was here they explained to 
me they haven’t seen this type of autism yet, that he has. So now I don’t have any appointments 
as yet until they have a meeting and discuss how they can handle him.” 
INTERVIEWER: “Okay. And do you think this study is going to help with that?” 
P5: “I hope so, because I need the help. I need the help with him… the last people that we saw 
they didn’t say they can give me a result, but tell me this is the reason why he has autism. So I 
don’t expect… like they explained to me they can’t say it’s genetically positive because they must 
first send the results away, or environmentally, so I’m passed that stage already to be honest, 
where I want to know. It’s my last child. So … I just want help for the future. I’m saying that right 
now.” 
INTERVIEWER: So the cause is not that important to you? 
P5: “It’s not important to me…But I’m saying I need like … like some sense of direction. Like I told 
them also, no offense of their profession, they know what they’re doing, but I don’t see a result in 
the sense where there’s help. Do you understand what I mean?” 
 
On the other hand, participants whose child remains undiagnosed experienced diagnostic and 
prognostic uncertainty and indicated that they consented to participate in the NeuroDev study 
partly because they were hoping the study could help them attain a diagnosis, thereby 
establishing a management plan. 
 
P15: “There was quite a lot happening with regards to my daughter. There were multiple 
abnormalities which we aware of before giving birth to her, but the uncertainty of not knowing 
what is going to happen. So a lot of emotions. Still is, but now and then, but we manage to get 
through it because we actually came to understand that no matter what tests are being done 
nothing is going to change. So I think the hope we have is just basically her vision. We’re hoping 
her vision will just be better one day, or that there’s something we can maybe do to just assist her 




Interviewees expressed the hope that participating in the NeuroDev study would offer a way to 
obtain more future certainty for participants through obtaining a diagnosis and through guidance 
in optimum management of their child. 
 
4.4.3 FULFILLING THE NEED FOR INFORMATION 
 
Participants were eager to learn more about their child’s condition – where it came from and how 
best to support their child – and expressed feeling unsupported by the healthcare system. 
Participants seem to express an expectation that the results from the NeuroDev study will fill these 
gaps. 
 
P2: “We’d really like to get to know the basics and details because not everyone goes in depth 
with this autism things. Like, here’s pages, read it, that’s what it’s all about, do timetables, 
schedules and stuff. So, I really like, want to know the whole details of autism, can it be cured, 
genetic-wise, how and where did it come from. Like if could just get a little more information about 
the spectrum…No. Like I’m just at peace I think, like I wouldn’t want … like, I mean, parents 
shouldn’t say I wouldn’t want a cure, but like it is what it is and he’s been diagnosed with this so, 
for me on the whole I would want like to find out information and genetic-wise plays a big role in 
this so. Like genetic-wise I would want to have more information of - to find out different things, 
but for now I quite know that there won’t be a cure. Because the only reason based on why this 
whole assessment that they’re doing is to find the reason why too much kids are being diagnosed 
with autism.” 
 
Some wanted to know what ‘conditions’ cause Autism, questioning whether factors such as 
obesity (i.e. maternal health) could cause their child to be affected from birth; or if some 





P1: “Just basically where it stems from. Like what conditions bring it on. Like I want to know if it 
was my obesity that caused this. Because you know, like you just … you read a lot of things and 
nobody really has any concrete evidence to say where this comes from, so I’d just be interested 
to know where it comes from. So if it is something from birth or if it’s something that happens 
afterwards, if it’s something that is activated by vaccinations. I’d just like to know just for interest’s 
sake, even if it turns out that there’s something wrong with my husband, and that it isn’t genetic. 
I would just like to know where it comes from. So whether it comes from vaccination. Anything 
that can help me in the future or help me to, you know, maybe navigate this better, or … like my 
main is just what caused it.” 
 
There was an obvious need for understanding their child’s condition and the reasons for the cause 
of it; and participants felt that through their participation in the NeuroDev study, these questions 
could hopefully be addressed. 
 
4.5 THEME 4 | UNDERSTANDING THE STUDY 
 
In this section I present a brief description and explore the understanding and recall of participants 
interviewed for this sub-study regarding which results the NeuroDev study would return, as 
explained to them during enrollment. 
 
Overall, people remembered the NeuroDev study and seemed to understand that they would only 
get results back if there were positive results. There appeared to be some confusion over which 
results were considered positive, with some referring to individual genetic findings (pertinent or 
incidental) and their role in the onset of the condition whilst others referred to a positive outcome 
which could mean a negative result (i.e. an issue of terminology over the use of the word positive). 
During this interview process, the interviewer did not set out to clarify such misconceptions at the 
start of the interview in order to gain an overall insight into participant understanding from the 
enrollment process, however, these misconceptions were corrected following the interview. The 
purpose of the NeuroDev study was aimed at a better understanding of the genetic architecture 
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of NDD disorders. Whilst most participants understood this, they still felt conflicted as to their 
beliefs over the possibility of specific causes such as an environmental cause, which added to 
the uncertainty mentioned above. 
 
P11: “Because I don’t know. That time when I came I didn’t think about the vaccine. I didn’t think 
about that. But when times goes on I was trying to figure out, you know, if you are a parent you 
are trying to think what went wrong and what … Sometimes you come out to say, no man, it’s not 
that, but some people, there are people from another country they don’t vaccine their children, 
especially in our country, there is a religion, they don’t vaccine, but there are some people with 
autism.” 
 
Participants generally understood that genetics and DNA is something that ‘runs in families’ but 
found it confusing that the condition of their children did not obviously run in their family. Only a 
few understood that changes in DNA (mutations) could occur in an affected individual for the first 
time and under those circumstances, they would not carry this mutation. Some carried a simplistic 
view; relating the condition to a single cause being either environmental or genetic; whilst many 
had some understanding of the concept of multifactorial inheritance, describing it as ‘many little 
things that come together at one point to cause the condition’ in their child or as cells that get 
activated.  
 
P12: “I look at it as, how I look at bipolar also. Like everybody has cancer cells. It’s just whether 
it gets activated. So maybe in that sense they’re looking at autism. Is it maybe a cell that lies 
dormant, that’s my understanding, as well as if it is a cell that lies dormant, what is it that maybe 









4.5.1 EXPECTATIONS OF NATURE OF RESULTS 
 
When asked what results these parents are expecting to receive, some felt it would be causative 
results explaining what the change in their child’s genetics is or ‘how it came in their genes’; others 
felt the results would confirm an inherited genetic cause; whilst yet others continued to believe 
results would show an environmental cause only such as environmental exposure. 
 
4.5.1.1 UNCERTAINTY OVER NATURE OF STUDY RESULTS AND ITS 
IMPLICATIONS 
 
Some participants indicated that they were anxious about the nature of the results they could 
receive and felt the meaning of the result would be dependent on the kind of result they would 
receive. 
 
P6: “It depends on what kind of result we’re talking about. If it’s like something to … what the 
cause is. Basically, there’s nothing we can do about it.” 
 
Because there was uncertainty over what the meaning and implications of possible results would 
be, participants were unable to speculate how those results would make them feel. 
 
P7: “I’m not sure. I’m not sure if it’s not going to help me with anything. Because I’m not sure … I 
don’t know if it’s going to be good or it’s going to be bad, or how I’m going to take it” 
 
Conversely, others were not expecting to receive any results, understanding that the NeuroDev 
study was for data collection purposes only. It is also noteworthy that participants observed that 
a long time has passed since they enrolled in that study and since any researcher contact has 






INTERVIEWER: “Okay. What kind of result are you expecting?” 
P9: “Nothing. [Laughing]…It’s been a while now already and it’s not even saying … we haven’t 
forgotten about you or something. So, yes, that’s why I feel … and I was actually surprised when 
you called. Okay, there is somebody still remembering us.” 
 
Uncertainty over the meaning of results and their implications created anxiety in participants that 
may have been caused by a lack of understanding which results would be fed back by NeuroDev. 
Whilst participants reiterated that only pertinent results would be returned, they continued to 
discuss the likely implications of non-causative or uncertain results. This is explored further in the 
following section. 
 
4.5.1.2 PERCEIVED UTILITY OF RECEIVING NON-PERTINENT RESULTS 
 
The majority of participants expressed their wish to receive all types of results, good or bad, 
including individual genetic research results that are of significance to the health of their child; 
and the confusion over the nature of results that the NeuroDev may return and the potential 
implications of their preference to IF was evident. Some believed that results could warn them of 
their child’s potential health risks. 
 
P5: “If it’s something that can affect him, then yes, we would want to know about it…And they pick 
up something else that’s not related, yes.” 
 
A few parents believed results would be indicative of their own personal health, also referring to 
incidental findings, mentioning that those findings could then be used to help others and inform 






P7: “Any. I can’t say I’m hoping for this, but any result that comes. Anything that they can find 
maybe some sicknesses in me or something maybe can … so that they can prevent it to other 
people…But if they can say the result is coming like this, this is something that we found that may 
cause your child to be like this, then I will accept it. The moment that they come with the result 
that says this is a condition we found but it’s not what caused this on your ch ild. That will be fine 
too. And then I’m going to look forward to see how they’re going to maybe help it or treat 
it…Everything they find. Everything.” 
 
Others felt it would enable them to provide a better quality of life by being prepared and planning 
for their family’s future. The latter was also described by a participant in terms of his own health, 
possibly driven by personal fears of having passed the condition to his child or another possibility 
being the confusion over the nature of the result he can receive, in other words an IF. 
 
P17: “Look, I mean if there is a result there’s a result. Obviously we have to know that. I’ve got 
dependents, five of them you know, so I would want to ... if I’m going to die tomorrow or in a few 
years’ time I would like to have that quality of life. I don’t just want to leave them behind or 
whatever. 
 
Some participants seemed to prefer to receive information about all kind of results, including ones 
that do not yet have clinical significance (results that are normally referred to as ‘variants of 
unknown significance’). They expressed the hope that those results could lead to further research 
that they could participate in. 
 
P1: “Maybe then someone else would come and try to take that further and then we can be 






These findings resonate with the reported results of published studies. For instance, the 
HealthSeq study (Sanderson et al., 2016) found that participants did not expect genetic testing 
information to be immediately available or beneficial, but hoped that continued research would 
provide more information in future. Furthermore, Halverson, Clift & McCormick (2016) and Miller, 
et al. (2008) found that participants found meaning in results of uncertainty and believed that 
knowledge about such results and analysis would grow, yielding answers in the future. 
 
On the contrary, some were unsure about the usefulness of VUS information and expressed 
concern over the possibility of discovering new/other information, indicating a preference not to 
know about VUS results. 
 
P16: “I don’t know if I would want to know that part, because now you’re going to be sitting with 
this information and you’re thinking what could this be.” 
 
Reasons for wanting all generated results stemmed from a need to plan for the future, to provide 
quality of life, to inform personal health risks and to promote future research and information 
discovery. 
 
However, some felt that receiving negative rather than all types of results (i.e. receiving feedback 
from researchers that no results were generated through the study) could reassure them that 
researchers tried their best to find answers, referring to closure and perhaps somewhat reducing 
anxiety, serving as confirmation of acknowledgement from the healthcare system and relieving 
their personal turmoil over having done all they could.  
 
P1: “Just to let the whole thing come to fruition, I mean like, just have it being done and we… not 
that I would feel like this has all been for nothing. I mean, I’ve been educated about some subjects 
with regards to this, and I know what you [researchers] do. And ja, I just think that I would be okay 
with even if they didn’t know anything, then at least I know that it’s over and that they’ve done all 




Others alluded to such findings having the potential to generate anxiety, representing new 




In this chapter I presented a brief overview of participant sociodemographic data and explored 
what participants understood regarding the NeuroDev study returns policy (Section 2.5.1.1) and 
their expectations of the impact results may have, aiming to address research question 1. Whilst 
a level of confusion was observed with participants taking a broader perspective on likely 
implications of all types of results, there remained understanding that pertinent results explaining 
the cause of their child’s condition would be returned. I explore the personal utility of receiving 
pertinent results in the following chapter.   
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In the previous chapter I discussed the understanding of research participants with regards to the 
nature of results the NeuroDev study would return. As mentioned, there appeared to be some 
confusion over the implications of results, with participants linking ideas over likely implications to 
not only pertinent results, but more broadly to all results that may be generated through a genomic 
research study. In this chapter I focus on participant perspective of the likely impact of pertinent 
results specifically – i.e. a diagnostic genetic result for their child’s condition – and their reasons 
for wanting to receive such results, since this is what the NeuroDev study will be returning. This 








5.1 THEME 5 | EXPECTATIONS ABOUT THE IMPACT OF PERTINENT STUDY 
RESULTS 
 
As previously discussed, overall participants expected the NeuroDev study to return results that 
explains the cause of their child’s condition (i.e. pertinent results), with the majority expecting a 




Participants clearly linked their own meaning to results and perceived them as useful for reasons 
other than just clinical utility. Such personal value included closure, whether overall closure or 










5.1.1 [DIAGNOSTIC] CLOSURE 
 
For participants, diagnostic closure was a major finding regarding their expectations. This 
encompassed acceptance of their child/situation, addressing guilt and blame and that it would aid 




Many participants expressed that whilst the unknown brings fear, results would bring awareness 
and acceptance - some form of peace. 
 
P16: “Awareness and being able to accept whatever it is and ... being able to accept something 
and being aware of it, it just makes you feel more at peace about whatever, you know, whatever 
the result is. But not knowing is scary. You don’t know how to deal with things and, I mean, we 
used to think that [child's name] is just being naughty, you know, and sometimes you feel bad 
because we used to scold him and give him a spanking whatever, and in the meanwhile he had 
this problem. So ja, I’d rather be aware and know, and then know how to treat it.” 
 
P10: “If it’s for example, a negative result we’ll work towards a solution and move on…Because 
looking back and moaning about it, is not going to help anyone.” 
 
An observation was made that for some participants, answers would bring relief regardless of the 
meaning of the result or the cause of their child’s condition. 
 
P11: “It would be a relief. Because now we’re just saying, okay, maybe ja, it’s the vaccine. But 
maybe it’s not. Maybe there’s something wrong with me and [husband's name]…So you know, if 
they come and say we found something on [name of child], yo, it will be … it doesn’t matter if it’s 




As noted in a study conducted by Halverson, Clift & McCormick (2016), participants who had 
exome sequencing done in a clinical setting perceived it as valuable to have a name for the 
condition or to know the cause. This could offer a sense of closure and relief by knowing that they 
have done all they can to ensure their health. 
 
5.1.1.2 GUILT AND (SELF-)BLAME 
 
Participants felt that results would resolve feelings of guilt and self-blame by offering an 
understanding of why this happened and where it stems from. Having answers would put the 
unknown to rest such as not knowing what it [the condition or the cause] could be, and they would 
be able to work towards a solution and move on by knowing that they did not do anything to cause 
their child’s condition. 
 
P15: “It will just be like closure. It will be … I did nothing wrong, my husband did nothing wrong. 
We didn't bring it upon her.” 
 
Many parents battled with questions as to why this may have happened and described being 
overcome with feelings of grief and guilt, which may have been somewhat relieved through 
participation in the study, either by the knowledge inferred upon them regarding their child’s 
condition or by the comfort of knowing that help is available. 
 
P13: “Yes, because, it’s just like a miracle because in my mind I was thinking, oh, maybe one day 
I can find some people who’s going to help me to understand about the situation with the baby. 
But God made a miracle, I met them [the NeuroDev staff] … after that I was very happy because 
I was always crying, oh God, what have I done. So there was time when I met them, so now I 
saw, oh no, it’s not mine. It’s not my fault. It’s God and he knows what he’s doing. But I was very 





It seemed that internal guilt may be exacerbated for some when the condition is not seen in other 
family members, possibly relating to the fact that they might have done something wrong to solely 
carry this flaw that they passed on to their child and also feeling guilt that their child expresses 
this condition which they too, carry. 
 
P7: “If it’s something that is in his DNA, it’s not something that comes from me, then I’m not going 
to be worried because I’m not going to feel guilty like I’m the cause of him being like that. I’m 
going to know that it’s naturally comes like that. But if it’s going to come like something that he 
get from me I’m going to feel guilty on the other side, because even when I look at him suffering 
or it’s difficult to do something I’m going to be like … you are like this because of me. But on the 
other side, I’m going to be glad that I give back to him so that I can know also that I have this 
condition, maybe I could’ve … maybe there was no chance that I can know what condition do I 
have there. Maybe this was a channel to give me the … to tell me about my body also.” 
 
For some, knowing that this is a spontaneous mutation, occurring in the child for the first time and 
not carried by them, may resolve such feelings of guilt albeit sharing the same DNA. On the 
contrary, for some results would not take such feelings away and the guilt affected extended 
family members as well, knowing that they had shared DNA and perhaps all carry this ‘flaw’. 
 
P4: “Since I hear that she is autistic I’m not well and if I can have a result now I think it’s going to 
be the same. My sisters and my brother also, they’ll feel bad but not as much as me … because 
I’m the mother. I’m the one who carried nine months in my tummy, so I will always feel bad.” 
 
Some were searching for confirmation that they were not to blame to assist in the process of guilt 
resolution. They felt they had done everything right during this pregnancy, whereas they had 





P15: “At the same time you’re a mother, you are human. You still want to know why. Even though 
a name is not going to change it, but it’s also, you want … what is that word? It’s just a need to 
know. Because when I, like in the beginning when we found out … the first thing we did we 
stopped smoking. That’s the first thing we did. So we did everything right. We didn’t do 
unnecessary going out. We just took it easy. In fact, I was more healthy with her to what I was 
with him [sibling] in my pregnancy. So I would like to know how and why.” 
 
The desire for answers as to the cause of their child’s condition and a basic need to know, was 
fuelled by various reasons and agendas. Participants described the need to know if it [the 
condition] is genetic, linking this to their decision-making over having another child (discussed in 
greater detail below). It is possible that participants may also have been searching for someone 
to blame or were looking for ways to resolve feelings of self-blame. 
 
P1: “So I definitely think - and this isn’t to just like prove a point then oh my God, you have ADHD, 
I’m going to leave you because I want more children. I just … I need to know. And this for me was 
the perfect opportunity to …I do believe that there is a deeper cause and I do believe that it stems 
from my husband’s side of the family and I do need to know.” 
 
5.1.1.3 SELF-EMPOWERMENT – WHAT’S IN A NAME? 
 
For those whose child remains undiagnosed, hopes were that results would bring a name for their 
child’s condition, thereby providing means for defined management and treatment of their child. 
 
P15: “I haven’t thought of it actually. For me any result … it’s like I said before, the results that I’m 
going to get are not going to change anything. So it’s just about knowing. It will be nice to have a 
name for her disorder because currently each department is just basically assisting her as per 
organ. She doesn’t have a place to go to. She’s all over at the hospital basically because she’s 




A name for their child’s condition would guide them in conducting their own research and foster 
self-empowerment. 
 
P15: “In a category. And it will also make things easier for research, for me. When I … like when 
we discovered when she was born this was wrong … it’s easy to Google once you have a name 
to something. But before they could tell me what was wrong with her eyes I was laying in the bed 
after giving birth and was trying to Google, born without a right eye, what does it mean. And ten 
thousand stuff came up and I’m like, now which one of these does she have. So, it would be nice 
to know.” 
 
5.1.2 IMPROVING THE MANAGEMENT OF CHILD ’S CONDITION 
 
For many becoming as educated as possible about their child’s condition meant that they would 
have greater understanding and be better able to manage their child. 
 
P1: “I mean, I just want to be like as educated as I can on the subject. Because I mean, it’s part 
of my life now.” 
 
P7: “I think it’s going to teach me something also so that I can know how to handle him, all that. 
Because if you know what is wrong with this person then you know what to do when you are 
around this person.” 
 
Having results could make things easier, raising hopes for treatment, medicines and an improved 
life for their child. 
 
P6: “Like maybe what medication he can use, or something. I’ve seen a video of a … I think the 
girl is 24 and she’s got autism, can speak and everything. She’s got her own school for autistic 
children that actually helps them, but it’s not here. It’s overseas. Basically just to help him to 




However, interviewees also expressed that nothing could be done about the fact that the child 
has the condition and that a genetic diagnosis would not change this. 
 
P6: “Basically we just want to know what the cause of Autism is and what we can do to make it 
better … you can’t do much about it.” 
 
5.1.3 RECURRENCE RISKS 
 
Receiving pertinent results can inform participants of their personal reproductive potential or that 
of their children. Some wanted to find out if they could have more children who would be 
unaffected, 
 
P1: “I remember like the main reason why we did it, was so that we could find out if we could have 
more children without the child having some type of neurological issue” 
 
while others more broadly wanted to help the next generation of their family. 
 
P7: “So I said I understand. I don’t mind no matter it’s not going to help me now, maybe it’s going 
to help my grandchild in the future.” 
 
Some wanted to know the likelihood of their child’s condition being genetic (referring to the 
likelihood of it being inherited) and what the recurrence risks are to the affected child’s future 
offspring. 
 
P1: “Maybe also just to know if it is genetic and she has it would her offspring then also have it. 




This is consistent with findings in the literature which note that for some healthy participants, 
expectations of research study results involved a desire for health risk information for their 
children or grandchildren which tied in with reproductive planning (Allen et al., 2014; Biesecker et 
al., 2009; Kauffman et al., 2017; Sanderson et al., 2016). 
 
5.1.4 RESULTS WON’T CHANGE ANYTHING  
 
Contrary to all of the above-mentioned reasons for receiving pertinent results, some participants 
felt that receiving a genetic result would be unlikely to change how they relate to their child and 
the condition. 
 
P12: “In all honesty, I … especially in the beginning when [name of child] was diagnosed, it’s … I 
would like to know why, would be fantastic. I can honestly say I haven’t come hundred percent to 
deal with the fact that my son has autism, but I can say that no matter the results, as to why … 
it’s not going to change the way I feel towards my son, it’s not going to change the things that I 
do for him, what I do or sacrifice. I feel with my family and myself, we would still have done 
everything that we did we would do again. It wouldn’t change it. So as to why he has autism, I just 
it’s just a bonus to know, but it won’t make or break anything…It won’t tell who my son is because 
I already know.” 
 
P15: “…it’s not like she has an illness and she has a thing where she’s getting worse. So anything 
they’re going to find is not going to change or make her worse. She is who she is, she has what 
she has and we’re administering it accordingly.” 
 
These individuals continued to hope for an answer but did not feel it would add further value other 








In this chapter I aimed to address the research question concerning participant reasons for 
agreeing to the return of positive NDD-related research results. I described how pertinent results 
has the potential to impact in a positive way for many participants who hope it could bring closure 
by bringing acceptance of their child’s condition, dissipate feelings of (self-)blame or guilt and 
offer means of self-empowerment. Furthermore it is meaningful in the sense that it could offer 
information regarding improved management for their child and inform risks for future offspring. 
Some felt however that although receiving pertinent results would be valuable in offering a reason 
for the cause, it wasn’t likely to change the outlook of their child’s condition or the management 
thereof.   
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The previous chapter focused on the meaning of pertinent results and why participants want such 
results returned. The chapter that ensues deals with participant preferences to the logistics of 
feedback of results, broadly presenting the how, where, what, why and whom questions often 














6.1 THEME 6 | THE VALUE OF A NEGATIVE RESULT –  ACKNOWLEDGING 
PERSONAL UTILITY 
 
Participant motivation for their decision to receive pertinent study results was to gain information 
and to find a reason for what is going on with their child, however, they felt that they would want 
to know if there was no genetic result as this would also guide their future planning. 
 
P2: “I’m quite fine. I’d also like to get information, but however they also mentioned that if they 
don’t find anything in our blood which means like, although they won’t contact us but it would also 
be nice if they could just say like your blood test came back, we’re going to have to work on 
something else and see whether the next step will be better. Because currently we find nothing. 
So that only would be appreciated a lot, then we can follow next procedures and stuff and wait for 
something else to come.” 
 
P12: “I mean, I would like to believe that everybody in that position would, you know, say 
something … the main thing to do, not just about ethics or anything, it’s just …” 
INTERVIEWER: “But that’s what you would want. You want all kinds of results back, it doesn’t 
matter what they’ve found?” 
P12: “Yes. I mean … anything’s better than nothing. Even if it’s just to say that look, we haven’t, 
you know, found … the study was inconclusive. I would also like to know that.” 
 
Regardless of their understanding of the NeuroDev feedback policy which stipulates that only 
pertinent findings will be returned (Section 2.5.1.1), the majority of participants wanted to be 
contacted with a negative result for various reasons, including getting closure, for peace of mind, 
keeping calm, and to stay informed of research progress. 
 
P12: “Yes. I think that is as important. I think it’s more for peace of mind and also to … it’s just 




For some individuals, receiving a negative result would bring reassurance that they and the 
researchers did the best they could, despite a lack of answers over what the meaning of the result 
may be or the lack of clinical utility. 
 
P1: “Just to let this whole thing come to fruition, I mean like, just have it being done and we … not 
that I would feel like this has all been for nothing. I mean, I’ve been educated about some subjects 
with regards to this, and I know what you do. And, ja I just think that I would be okay with even if 
they didn’t know anything, then at least I know that it’s over and that they’ve done all they could 
and that it’s still a mystery.” 
 
A sense of entitlement over their blood and thus their results was apparent in a few individuals. 
 
P7: “I prefer they must call me to tell me that. Because I’m going to sit like now, that year in Red 
Cross they take my blood and they say I didn’t know what they’re checking, I didn’t know if there’s 
anything that they found in my blood, but that is quiet. Nothing happen after that. I would like to 
… because it’s my blood, I would like to contact me and tell me even if they didn’t find anything.” 
 
Whilst many understood that researcher constraints, such as budget restrictions and the large 
number of participants enrolled in the study, may not allow for the feedback of negative results, 
they expressed their appreciation for such feedback. 
 
P16: “Yes, I would appreciate that. I do know however that there is a budget for all of this and 
that, I mean, there’s probably hundreds if not thousands of people enrolled in this thing, so it’s not 
imperative that they have to call if they don’t find a result. But if they are able to do so then, yes, 
I would appreciate getting a phone call.” 
 
Religion formed a strong foundation for some when it came to acceptance of the lack of results 




P13: “Even if they didn’t find anything, if God is fine, so we’ve got no problem. Because some 
things only comes from God. So even you can test and do your things, but if they comes from 
God there’s nothing we can do. We can accept it as we say. And then they gonna help us with, if 
they find another thing they can call us and help us. We’ve got no problem about that.” 
 
Participants seemed to feel a sense of ownership over their blood or their contribution to the 
research study, finding meaning even in negative results. In other words, a negative result would 
be a meaningful return for being part of the NeuroDev study albeit the lack of an answer as to the 
cause of their child’s condition. They viewed such a result as an answer in itself, with the potential 
to bring closure, peace and acceptance, perhaps through the knowledge of having done all they 
could. 
 
6.2 THEME 7 | PREFERENCES FOR EXPLANATION OF PRELIMINARY RESULTS 
 
In investigating participant preferences for the RoR, it became apparent that tailoring such 
information to a standard guideline would be complex given the vast diversity in preferences of 
which results should be returned. Adding to the importance of resolving this dilemma would be 
considerations of what participants consider appropriate timing of feedback. 
 
6.2.1 HOW MUCH IS TOO MUCH? 
 
Information-load preferences for second sample contact varied from wanting a broad 
explanation/generic information as to why a second sample was needed to wanting a detailed 
explanation of preliminary results (See Section 2.5.1 in Chapter 2).  
 
A broad explanation included the reason for wanting a second sample and what it would be for, 
i.e. was the first sample tainted or did the researchers just need more information. In order to 
eliminate worry and anxiety, some felt a need to not know what was found at this stage and only 
required generic information, being told that there is a likely result which needs to be verified. 
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Others however, wanted all information and detailed explanations at the time the second sample 
was obtained, including what the preliminary result is that requires verification and to have it 
explained in a comprehensible manner. Some alluded to expecting transparency with regards to 
researcher uncertainty over the meaning of results. Reasons for this was to be aware of findings 
and the process, to see which tests were done and what treatment is available. Others wanted to 
be a part of the process, to be kept informed as to the progression of the study and to understand 
the process of testing as well as how researchers came to the results. 
 
P15: “Just basically why and what they found out. At what point are they at and how they actually 
came to that conclusion, or, yes, it’s a test but what made you to actually do that particular test, 
to go that route.” 
 
However, it is of importance to remember that participants would automatically assume a genetic 
pertinent variant was found if second sample contact is made and that the impact of such 
knowledge should not be underestimated. 
 
P1: “Obviously I would know then that it’s got something to do with our genetics. So I’d probably 
wouldn’t want to know because then I’m going to mull over it for the next couple of months while 
they do the second sample. So I would just assume that something is up with one of us and that 
they will have to verify it. So I’d prefer to get like actual information rather than this could be and 
that could be and we’re still busy with that.” 
 
It is evident from the above that participants have diverse preferences and that such diversity 









6.3 THEME 8 | TIMING OF FEEDBACK 
 
When asked whether participants would want to be told of the preliminary result when the second 
blood sample was taken, preferences seemed to vary once again. As previously described, 
participants understood that the NeuroDev study would not feedback preliminary results (see 
NeuroDev policy, section 2.5.1.1). 
Almost half preferred to only be told of the result after verification. The most prominent reasons 
for wanting to be told only after verification included avoiding unnecessary stress and worry over 
an inconclusive result, the need for certainty and to maintain peace of mind. 
 
P3: “But it has to be something that they’re certain about, like, okay we found this, like they know 
they found and let us know what the … not something that they’re not sure about. Like if they 
don’t know yet if it is that, so, they just need to be certain that they found this in the blood…” 
 
Participants were happy to wait longer for results if waiting would assist in maintaining peace of 
mind. 
 
P1: “Because I want like solid evidence that this is what they’ve found. I don’t like this could be 
and that could be and then take the second sample and then it’s like a totally different ballgame 
and that’s why I’d prefer end results and in fact we’re willing to wait longer for that.” 
 
However, others expressed their desire for receiving preliminary results, indicating a need for 
study involvement and to be prepared for the possible outcome. 
 
P15: “I would like to know that yes. Like what is it and why? What did you pick up that you just 




P11: “A lot of reasons. Because sometimes I want to know what they found and why they are 
taking another sample. Maybe they found something good or bad, so I want to know. And then if 
I do the next step I will be knowing what they found.” 
INTERVIEWER: “So you’d be prepared for the next step going forward?” 
P11: “Yes. And I don’t mind if they come again like now, oh, we lost or we need some more, we 
want some more blood, or we want you again, I don’t mind. I want to come.” 
 
Further reasons included wanting to know if they needed to be concerned, the desire to assist in 
the research being conducted but expecting researcher transparency throughout, the right to 
know and be informed. 
 
P15: “I would like to know that yes. Like what is it and why? What did you pick up that you just 
want to verify. Yes, I know maybe it’s not it, but just so I know exactly where they are heading. It’s 
also the need to understand how they got to the point. So yes, they found something they’re not 
sure and they need to double check it. But it would be nice to know that you guys actually … 
there’s some type of progress. Because it’s going somewhere and not just, we’re back here 
again.” 
 
There was a perceived potential for preliminary results to cure or treat their child, possibly referring 
to the timeous receipt of results and early intervention. 
 
P14: “In case there’s something maybe we can fix.” 
 
As can be seen, the timing of feedback may have a degree of psychosocial impact for some or 







6.3.1 WHO SHOULD EXPLAIN RESULTS - FAMILIARITY 
 
While some participants felt that they had no preference about who returned their results, most 
preferred the news to come from the original study researchers. Expectations were that it be a 
professional capable of explaining everything to participants in an understandable manner, 
someone the participant is familiar with and who listens, and someone who is familiar with their 
child, knows their child’s background and who participants feel comfortable with asking questions. 
Some mentioned that they would be comfortable hearing results from other doctors or general 
practitioners known to them if the researchers on the NeuroDev study experienced time or 
resource constraints. At the time of feedback, participants expected thorough explanations and 
reassurance from the person who would be giving the feedback. 
 
P12: “Hmm. But it also depends on how it’s explained. Like how you explained, you are part of 
the feedback, etc., and that made me feel at ease when I speak to you. So if everybody has their 
different roles to play in that way I can understand speaking to somebody completely different. 
But if it’s … I think the way you guys have done it overall, it’s fine how it is. You guys explain 
yourself very well and make it clear. So …” 
 
Many wanted to be told by a doctor who is involved in their child’s management and placed their 
trust in the doctors at RCWMCH.1 
 
P13: “Yes. Or even the doctor because this child is going to Dr [name]. Even the doctor explain 
us it will be fine. I would be happy with that. Because the doctor knows everything of the child.” 
INTERVIEWER: “And how would you feel if it was some other doctor?” 
P13: “No problem…. No, I’m very happy with the doctors at Red Cross. I’m very happy.  Because 
the first time when I came to Red Cross I met different doctors. So all of them I was very happy.” 
 
 
1 In the NeuroDev study, the PI’s are part of the clinical team overseeing the participants’ children and the study is 
based at Red Cross War Memorial Hospital in Cape Town.  
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Overall the feeling seemed to be that researchers involved in the NeuroDev study would foster 
feelings of ease, could answer whichever questions arose with the results, have knowledge and 
insight of the individual’s medical background and journey and are well-suited to explain the 
necessary information to participants. Familiarity was a key factor influencing preferences 
regarding who should deliver results. 
 
6.3.2 WHERE & HOW – RESPECT & CONFIDENTIALITY 
 
When participants were asked where they would like to receive feedback regarding their results 
after verification, consensus was that they should be called to come in to RCWMCH and be told 
in person. Many felt a WhatsApp or text message to set an appointment would be fine, although 
one participant was concerned that a text message could be missed and preferred a phone call 
to schedule the appointment. While some felt it would be alright to be given a negative result over 
the phone, it was thought that a face-to-face encounter, even with negative results, would alleviate 
anxiety and worry that ‘something bad’ was found. A few participants stated not wanting to be told 
telephonically, with one reason being a distrust of technology and fear of breach of security. 
 
P10: “The lines are never secured. You can’t say something is secured because even computers, 
cyber security, that’s big.” 
 
One participant who had a child with an undiagnosed condition stated that results would not 
change anything for her child in terms of management or treatment and therefore a letter or email 








P15: “It can be a letter, it can be e-mail as well. I’m okay with that. Like I said, it’s not like I’m going 
to need counselling because whatever diagnosis and treatment … there is a treatment for her, as 
basically if her kidneys are acting up it’s antibiotic, it’s normal. Her eyes, it would be her eye-drop, 
because she has an eye infection. So it’s not like she actually needs to go … like you know, you 
get very sick children. For us she’s not sick. You see, there’s a difference. So it doesn’t … It’s not 
going to change her life for the worst…There won’t be counselling needed. [Laughing].” 
 
Overall, most mentioned that their/their child’s private information would only be shared amongst 
researchers involved in the NeuroDev study, however, participants seemed to value 
confidentiality with some seemingly anxious about sharing private information on public 
databases or telephonically as described by P10 above and P16 below. 
 
P16: “They [NeuroDev researchers] also asked us if we would mind having [child’s name] picture 




This chapter aimed to address the research question related to participant preferences for the 
feedback of positive NDD-related research results. Clearly, it remains essential to foster an open, 
trusting relationship with research participants and to protect them as far as the application of 
ethical principles in research allow. The desire for study involvement in the research process and 
the need for information as research evolves is consistently reiterated by study participants; 
offering such information may promote or maintain participant emotional wellbeing by creating 
more certainty for them and foster a sense of not being forgotten. Interestingly, research 
participants appear to be more resilient than we may expect and seemingly have greater 
understanding of the resource constraints researchers may experience. Transparency may be 








In this dissertation I presented the results of an empirical study that aimed to explore what 
NeuroDev research participants understood regarding the study they consented to participating 
in, their reasons for wanting to receive positive individual NDD-related genetic results, and 
recommendations for how best to return such results. In this chapter, I will discuss the research 
findings and their implications for informing a feedback policy which takes research participants’ 
preferences and understanding into account. 
 
Participant understanding of the cause of their child’s condition 
In this study, I enrolled the parents of children with neurodevelopmental conditions who had 
enrolled in a NeuroDev study. For these parents their understanding about the cause of their 
child’s condition extended to their beliefs of maternal health or environmental factors playing a 
role. Health was also at times related to genetic inheritance insofar as having inherited the genes 
causing their (participant parents’) ill-health from their parents. Some expressed that a 
multifactorial element to disease causation may exist such as cells being activated by ‘triggers’, 
which were possibly of a genetic nature. 
 
One important observation of this study is that there is a tension between how genetics is 
explained to participants in the consent process – namely, ‘as something that runs in the blood’ – 
and their own observations that the condition affecting their children did not affect other family 
members. This intersects with confusion, expressed by many of the participants, about the 
concept of a de novo mutation which could lie at the basis of their condition. This is consistent 
with findings by Faure et al. (2019) who described that participants living with Rheumatic Heart 
Disease in the WC also described genetics as ‘something passed down in the blood’ but had 
difficulty explaining how these genes may be passed on through the family lineage. 
In this study, I found that once participants started to engage with the idea of a de novo mutation, 
this impacted on feelings of internal guilt, exacerbated by the lack of expression of the condition 
in their family, leaving these parents feeling solely to blame for the condition in their child either 
through carrying this ‘flaw’ themselves, feeling that their personal health was the cause, or that 
they may have done something or been exposed to something which caused the condition.  
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Furthermore, whilst only a few alluded to the concept of multifactorial inheritance of NDDs, this 
was only vaguely understood by some. Whilst there is a dearth of empirical data exploring how 
genetic attribution impacts on perceptions about illness on the African continent, what little 
evidence there is has focused either on broad ‘genetic knowledge’ (Faure et al., 2019) or on 
monogenic conditions (Marsh, Kamuya & Molyneux, 2011; Meilleur et al., 2011). The observation 
in this study suggests that there is an equally important question about how people engage with 
and understand de novo mutations playing a role in disease causation. 
 
• Terminology differences 
Interestingly, distinctive terminology was observed as participants referred to positive results as 
something which has a good outcome without implications and negative results as a ‘bad’ 
outcome. This is contradictory to the medical use of the terms positive results, meaning a 
pertinent/clinically significant result was identified, and negative results, meaning there were no 
results. It is imperative that researchers remain aware of this difference in description as this may 
need to be addressed and clarified either during the consent process or during results delivery. 
 
What motivates people to participate in research 
Participants described two reasons for their participation in the NeuroDev study which are in direct 
tension with each other, namely altruism and the expectation of personal benefit. 
Amongst these, the motivation that was most frequently mentioned by research participants was 
altruism. Participants discussed their challenges and being willing to go through great lengths to 
save others from the same fate. Research formed part of this altruistic act in that participants 
seemed to conceptualize it as the one thing they could do to make a difference by contributing to 
information and awareness about such conditions, thus reducing or prevent NDD-related 
conditions from occurring. This was also observed in a study by Sanderson et al. (2013) where 
participants expressed their willingness to participate in genomics research to help society 
understand and improve their health and to help others in general to ‘not go through what they’re 
going through’. Similar findings by Masiye, Mayosi & de Vries (2017) in a study in the WC also 
suggest that altruism is a strong motivator for participation in genomics research.  In my study, 
they hoped that their participation would result in a better understanding of their child’s condition 




The second motivation for research participation was for personal and family benefit. Participants 
hoped that, through their participation in the study, they would gain more information regarding 
NDDs which would result in the development of better strategies in managing NDDs. They further 
hoped that the study would generate genetic information that could inform recurrence risk for their 
family and could offer them the chance to plan for their family’s future . 
Obviously, there is a careful balance between participants expecting some personal benefit from 
research participation, and the challenge of therapeutic misconception, where people do not 
meaningfully distinguish between healthcare and research and think that their research 
participation is part of their healthcare (Tindana & de Vries, 2016). In this study, participants did 
seem to know and recognize that the NeuroDev study was a research study, offering no 
personal/family benefit, and was not part of the routine healthcare of their children, as they 
reiterated what was relayed to them during the consent process about it being to help future 
generations and understood the possibility of the study not finding genetic answers, but some still 
held hope for a cure/treatment, even if this was a distant future outlook made possible through 
many studies to come, of which NeuroDev may only be the start. 
 
Overall, perceived benefits to participating in the NeuroDev study included self-organization into 
advocacy as participants used the NeuroDev enrolment experience as an opportunity to link to 
other parents, forming their own support groups and taking personal control by conducting their 
own research using the knowledge they had gained in the process. 
 
Return of research results and participant preferences to receiving results 
In this study, it was apparent that the majority of participants wanted results of clinical significance 
related to the health of their child or their personal health and not a ‘data dump’ which they would 
struggle to make sense of and which they felt could have the potential to aggravate anxiety. 
With regards to the return of pertinent findings (i.e. findings related to their child’s condition), 
participants were keen to receive such results in order to help them understand their child’s 
prognosis and enable the best management strategy. Participants in this study group generally 
expressed different reasons as to why they would want pertinent results which included the need 
for help in ‘navigating’ the condition and bettering their situation; the need for more information as 
to the cause; help in understanding the condition and the difficulties the child faces; and being 




They also described the expectation that pertinent results could offer closure, bringing personal 
acceptance, relief and the ability to move on. There was a notable difference regarding the 
meaning of results between those whose child already had a diagnosis and those who didn’t. 
For those whose children had a diagnosis of autism, receiving pertinent results could potentially 
impact on reproductive planning for individuals and hence lead to the prevention of such NDD 
conditions from occurring. 
Participants whose child remained undiagnosed faced the emotional trauma and challenges 
associated with unanswered questions regarding their child’s diagnosis, what they could do to 
help their child, and what the future could bring. Overall, results related to their child’s condition, 
was hoped to impact positively on attaining answers for those with undiagnosed NDD-related 
conditions and to reduce uncertainty over the future. 
 
The return on non-pertinent findings (i.e. findings not related to their child’s condition) still held 
value for some participants as they perceived it as a result which may provide answers to issues 
relating to future health, either of themselves or their children, and could offer them a chance to 
prepare or plan for their future. Furthermore, for those whose children remained undiagnosed, a 
non-pertinent result still held the potential for answers as to their child’s medical challenges and 
the prospect that future research may bring answers, regardless of the meaning or cause 
identified. 
 
Generally, the RoR was seen by many as a point of access, either to information regarding their 
child’s condition or concerning help with the management of their child. This was not particularly 
related to direct benefits from participating in the NeuroDev study, but rather related to increasing 
knowledge surrounding these conditions which could lead to better management strategies. This 
finding is consistent with findings in the literature regarding participant perspectives over the utility 
of participating and receiving genomic information being a means of gaining information about 
their health or the cause of their condition and accessing quality care (Hall, Michael et al., 2015; 
Hylind et al., 2018; Traore et al., 2015). As mentioned previously, in this study, motivations for 
participating in research and reasons for wanting research results overlap as they are both 





Given that there is this overlap between what drives participants to participate in research and 
the reasons and expectations participants assign to receiving various kinds of research results, it 
may be important to consider the perceived value and meaning participants attribute to results in 
addition to assessments of clinical utility or medical actionability, as participants may classify 
these concepts differently to researchers (Holm et al., 2015). For instance, participants in this 
study clearly described that negative results would also be a valuable return for their participation 
in the NeuroDev study and would confirm that they themselves and researchers had done all they 
could to discover the cause. Such results have the potential to bring closure, peace and 
acceptance. Taking participant preferences concerning results disclosure into account has the 
potential to lead to greater participant satisfaction as well as increase public uptake of genomic 
research participation (Holm et al., 2015), improve participant heterogeneity and improve 
adherence to the research program (Scherr et al., 2018). 
 
• What they want to know and when – Results feedback process 
Participants gave diverse preferences concerning the results feedback process, however, overall 
perspectives were the desire for certainty over the cause and course of their child’s condition, 
familiarity with the person(s) delivering the results, researcher transparency, and the call for 
respect and confidentiality from those feeding back the results and concerning the sharing of 
results. Furthermore, amidst the preferences, participants held conflicting views regarding the 
best timing for delivering results but voiced the need for study involvement throughout the 
research process with some even expressing a desire to continue on a future research journey. 
One important observation relates to the need to take a second sample to confirm the original test 
result – which is a question raised by the NeuroDev study team and described in the literature 
review chapter. Namely, the issue is that pertinent results cannot be fed back to research 
participants unless it has been verified by a CLIA-certified laboratory but such further testing may 
require an additional blood sample to be taken. Participants in our study described that they would 
automatically assume a pertinent variant is found at the time of contact for a second sample since 
this was explained during the consent process; and it has the potential to create anxiety for some 
individuals. Whilst some welcomed the opportunity to prepare for the possibility of a positive result 
and perceived a potential for preliminary results to offer a chance for early intervention, others 
preferred to receive no explanations; researchers face the challenge of dealing with managing 
participant anxieties during this process. Another consideration is that participant expectation of 
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receiving results from the study was influenced by the time since last contact with researchers, 
where a greater time lapse since contact seemed to lower any expectation of receiving results. 
 
• Stigma 
A topic raised above is the common challenge in genomics research that relates to the potential 
for it to cause or aggravate stigma. As described by de Vries et al. (2013) and Tekola et al. 
(2009a), genomic research has the potential to reinforce pre-existing forms of stigma which may 
be attached to certain conditions. Whilst stigma is a complex concept that is the result of political 
and social processes and not just of attribution (Link & Phelan, 2001), this study did reveal that 
this could be a factor to consider in the conduct of genomics research on NDDs. For instance, 
some participants in this study mentioned the possibility of being personally responsible, 
experiencing a lack of understanding from family and friends, denial over their child’s condition 
either by close relationships or in the form of self-denial, and feelings of being judged. Whilst none 
of these constitute stigma, they involve feelings of guilt, denial, lack of understanding, or blame. 
In a study conducted by Oti-Boadi, Dankyi & Kwakye-Nuako (2020), it was clear that the mothers 
of children with ASDs experienced negative feelings towards themselves and God and were 
treated differently by family and friends.  Whilst I did not specifically probe experiences of stigma 
in the interviews, participants did relate feelings of guilt or blame which, according to Selman et 
al. (2018), may possibly be related to felt stigma. Namely, some participants in my study described 
that finding answers as to the cause of their child’s condition would inform them that they are not 
to blame and could assist in creating awareness about the condition. This is consistent with 
findings from Selman et al. (2018) that parents resist and counter the stigma they experience by 
learning and educating themselves about their child’s autism and according to Broady, Stoyles & 
Morse (2017), such knowledge could also be used to educate the public about the cause of such 
conditions, leading to diminished stigma. Other participants in this study describe initially blaming 
themselves for their child’s condition but through knowledge inferred during the NeuroDev study 
have come to realize that it’s not through their actions nor that they are personally ‘flawed’, but 
rather expressed it positively as the will of God. 
The emphasis of an (inherited) genetic link may create anxiety for biological relatives in that they 
may personally feel responsible for child’s condition, potentially exacerbating feelings of being 
‘flawed’ and at fault and can in such a manner be related to stigma, termed associative stigma 
(Faure et al., 2019). Often such feelings are heightened by the individual’s community beliefs or 
values regarding the cause of such conditions (Faure et al., 2019). 
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Interestingly, Faure et al. describes how genetic information also has the potential to reduce 
stigma, since knowing the cause can decrease (self-)blame in an individual by allowing that 
individual to feel less responsible for the condition given that it was not under their control (Faure 
et al., 2019). In other words, genetic information can reduce blame but increase the sense of loss 
of control and feelings of hopelessness in these individuals, all of which relates to internalized 
stigma. 
In a nutshell, whilst not the same as stigma, feelings of guilt and (self-)blame relate to stigma in 
that the caregivers of children with NDDs, particularly ASDs, often experience stigma (felt stigma) 
from family, friends, the child’s school or the public in numerous ways namely, through lack of 
knowledge, judgement, lack of support and rejection (Broady, Stoyles & Morse, 2017). These 
parents internalize these feelings, blaming themselves for their child’s condition , or feel 
responsible (guilt) and ultimately experience shame (Oti-Boadi, Dankyi & Kwakye-Nuako, 2020). 
From this study, there was some expectation that the RoR would impact on resolving feelings of 
guilt and sometimes (self-)blame as many participants alluded to seeking confirmation or 




This dissertation aimed to explore what research participants partaking in the NeuroDev study 
understood about the study, what their reasons were for partaking in this research and for wanting 
pertinent results returned, and recommendations for informing the feedback of results. 
The empirical work conducted for this thesis suggests that it is essential to consider the following 
pertaining to participant preferences, 1) the personal utility of results and that there may still be 
value in knowing a negative result; 2) preferences remain diverse and tailoring information for a 
set guidance policy will be complex; 3) participant need for certainty of results may contrast the 
need for study involvement and participant thoughts on appropriate timing of feedback may vary; 
4) familiarity is important for participants when considering who should communicate results, 
where it should be done, and who should be involved in the process; 5) participants have a need 
to maintain their dignity and should be shown respect when determining means of contact and 
methods employed to return results. In-person contact and the time afforded them may still be 





Through embarking on genomic research results delivery, many challenges continue to surface 
when considering research participants’ perspectives and preferences. Such challenges need to 
be addressed in order to facilitate a guidance framework for delivering genomic research results. 
Perhaps a GC has a valuable role to play in these situations and it has been well documented 
that it would be appropriate for a GC to be part of such a process (Middleton et al., 2017; Wonkam 
& de Vries, 2020). GCs may add value and are trained to address issues of uncertainty as well 
as psychosocial issues of guilt and blame, thereby enabling individual/parent adaptation to 
circumstances compounded by a medical condition and laying out a management plan going 
forward (Joseph, 2018). They can tailor the delivery of information to participants and have the 
appropriate set of communication skills and the ability to explain genetic concepts in a 
comprehensible manner, which may alleviate confusion regarding such concepts and their 
inheritance (Accreditation Council for Genetic Counselors [ACGC], 2013; Berrios et al., 2018). 
GCs can link participants to external resources such as appropriate healthcare professionals or 
support teams and to the latest developments in research information as well as possible projects 
or therapies (Joseph, 2018).  Overall, GC’s can act to bridge the gap between researcher and 
participant by being available to address concerns and through following up with participants 
regarding the progress and stance of the research (Benjamin et al., 2020), and can in such a 



















Given the diversity in participant preferences, understanding of genomic results and individual 
circumstances, it remains important for researchers to understand the psychosocial impact of 
genetic testing and that findings cannot be generalized from one context to another. Adding to 
this, it is vital that the consent process incorporates an understandable and culturally appropriate 
‘framework’ (Munung et al., 2016).  As such, I propose the following recommendations. 
 
1. VUS and IF appear to be important additional aspects to consider in the feedback of IF 
(FIF) debate and bodies considering FIF guidelines should consider ways of addressing 
these issues in a manner that support researchers that are planning to do FIF to navigate 
this ethically and medically complex area. As such, a tiered-consent model may need to 
be considered with options for which kinds of findings participants would like to receive; 
and 
2. This tiered-consent could be supported by a follow-up information session describing what 
these results could mean and giving examples of related conditions, how people could 
use these results and whether they have the potential for clinical therapeutic benefits 
locally. Such an information session may not need to be a) done at the same time as the 
primary consent, and b) does not need to be individual but could be group-based. 
Addressing the genomics research challenges that arise in the SA context with regards to 
diagnostic and therapeutic benefits versus the potential harms and providing adequate 
information to participants remains an essential component in supporting the right of the 
participant to accept or decline participation in genomics research studies (Nembaware et 
al., 2019).   
 
Furthermore, given the delay in return of genomic research results due to samples being 
processed in large batches, it may be useful to discuss participant preferences regarding the 
timing of receiving information about results. In cases where the participant cannot be 
accommodated, it may be useful to have a discussion where reasons for this could be explained. 
The following may be helpful suggestions for a practical approach, namely WhatsApp information 
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to give participants an idea of when the batch of their sample is likely to be processed, reassuring 
them that negative findings will be fed back via their main care provider or information sessions 
with the doctors that care for these families so they are also able to give families updates at their 
clinic visits. In this way, the researcher fulfills their obligation of communicating the planned 
process for disclosing results and is better able to manage any anxiety or ‘unhappiness’ and in 
so doing, maintain the trust of the participant and promote their psychosocial health and well-
being. 
Whilst serious effort has been put into ensuring that participants understand what they are 
consenting to, an interactive process may be necessary and this information could certainly assist 
treating clinicians in answering the questions as well. This will allow the research to play an 
appropriately supportive integrated role with clinical interface for these families. Clarifying 
confusion over participant understanding of heredity or genetic concepts and addressing 
terminology discrepancies between the participants and medical community can eliminate the 
possibility of confusion. Remaining aware of such discrepancies, some of which may be 
colloquially-based, and explaining any differences can aid in unifying language and 
communication, helpful in the goal to attaining standardized guidelines in future. Whilst this may 
be particularly helpful to address in the beginning stages of consent, it is suffice to say that such 
differences and confusions may likely need to be corrected throughout the research process as 
they arise. 
 
Finally, given that participants find personal meaning in negative results and generally seem to 
want such ‘answers’, the absence of a positive pertinent result may also need to be communicated 
during the initial stages of consent. In the event that a participant desires such results, any 
limitations in being able to deliver it should be openly communicated. In the even that no result 
has been found yet, perhaps a newsletter or an informative event could facilitate in keeping 
participants abreast of research progress in the event that they haven’t been individually 
contacted. This could provide participant satisfaction of being involved in the study 
process/progress and illustrate researcher transparency. 
 
A tiered-consent model focusing on participant perspectives regarding FIF and clearly 
establishing understanding of the implications of such findings could facilitate the development of 
a context-appropriate results delivery system, thereby protecting participants from potential 
exploitation and supporting their rights and wellbeing, thus leading to greater satisfaction for 
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participants and a positive relationship between the research industry and participants (Harris, 
Erin et al., 2012; IRCM Working Group, September 2015).  
Beyond this, the scope of GC roles could also include adequate, African-centric explanations of 
genetic concepts and inheritance (including multifactorial heredity), aid in addressing and 
clarifying issues of terminology, and could assist in easing the burden of researchers who may 
face time and resource constraints when attempting to ‘revisit’ participants. Addressing all the 
above issues of confusion over heredity and the nature/implications of results, issues over 
appropriate timing of delivery and personal preferences over extent of information wanted, 
preferences to receiving negative results or other kinds of results, as well as the continued contact 
























7.2 STUDY LIMITATIONS 
 
Influence from the researcher is inevitable due to the researcher and participant interacting in a 
social process (Korstjens & Moser, 2017), so it was essential for the researcher to be aware of 
personal bias, idiosyncrasies, values and beliefs whilst conducting the research so as not to 
influence the results in any manner. The researcher took field and observational notes, practiced 
reflective techniques and discussed any arising personal opinions/issues with a supervisor in 
order to maintain objectivity. As a GC student, it was also important for the researcher to be aware 
of the influence that her role as a student-clinician had on the research process. This was 
managed through creating rapport with research participants using the researcher’s own role as 
a mother, through continuous reflection and through continuous learning processes about cultural 
awareness, for example reading about the topic. 
 
Given that the researcher is at a novice level within the qualitative research field, initial interviews 
may not have been as well performed compared to later interviews in that certain cues or 
important concepts may have been missed or not explored initially, which became apparent later. 
 
Data may be slightly skewed by the limitations of recruiting subjects from a purposive sample 
obtained from the NeuroDev study and by participants who agreed to come versus those who 
could not be reached or who declined. This work is the first study that explored participant 
expectations for the return of pertinent individual genetic research results. Whilst it has shed some 
insights into what NeuroDev participants would like to know, the sample was small and narrowly 
tied for a particular condition. 
 
Although it was believed that data saturation was reached for this study given that similar themes 
and concepts surfaced across interview data, the researcher acknowledges that there is always 
a possibility that data saturation was not reached. Furthermore, although sample size was 
sufficient for this method of research, a number of participants could not be reached for 





Given that sociodemographic data was not obtained by the researcher, certain aspects cannot be 
represented. These may include social circumstance, financial stance/household income, 
parental ages and demographic location. While these are important influences on the way 
individuals cope, these data were not considered essential to this study and so from a perspective 
of “data minimization” the researcher decided not to collect it. The only information included was 
the gender of the parents being interviewed, the condition of the affected child and their ethnic 
background. 
 
Couple interviews were conducted in some instances which may have influenced the researcher-
participant communication process of personal thoughts or beliefs of some individuals. This did 
not seem to impact substantially on the overall outcome however.  
 
A final limitation to some of the interviews was that some research participants unexpectedly 
brought their children along to the interview. This made the interviewing process difficult as it was 
constantly interrupted and at times not focused. The recordings in these sessions were difficult to 
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APPENDIX A – PRELIMINARY OPEN-ENDED INTERVIEW GUIDE FOR “PARENTAL 
PERSPECTIVES ON THE RETURN OF PERTINENT GENOMIC FINDINGS” STUDY 
AT UNIVERSITY OF CAPE TOWN 
 
1) What do you remember about enrolling in the NeuroDev study? 
o What happened on that day? (PROMPT: mention names of recruiters (Emma, 
Kirsty, others)) 
o Do you remember signing a form? Do you recall what the form was about? o Did 
you give blood? What was that for? 
o Do you remember what was explained in the consent form? 
 
2) Could you tell me about the study you are participating in? 
o What is NeuroDev about? (PROMPT: genomics? why NDDs?) 
 
3) What do you believe to be the reason for your child’s condition? 
o What is it like living with a child with an undiagnosed condition? 
 
4) Why did you choose to participate in this study? 
o What do you think your chances are of receiving a result? 
o Do you remember what kind of results they said you can receive? (PROMPT: Only 
NDD-related/only if they know what the result means for their child/even if they 
don’t know what the result means) 
o What kind of results would you like to receive? o What kind of result are you 
expecting? 
o What would it mean for you and your family to receive a result? (PROMPT:  







5) Do you remember when they said they will give you a result? 
o PROMPT: after 2nd sample is taken and verified o When would you want to hear 
about possible results – before the 2nd sample is taken or only after validation? 
● What are your reasons for wanting/not wanting the results before 
verification? 
o If we contact you, how should we do this? (PROMPT: phone call, hospital) o What 
would you like to know when we take the second sample? 
o Would you want to be contacted with a negative result? 
 
6) If we have a verified result, where should we give this result to you and how? (PROMPT: 
At 
RXH, at home, phone or Skype) o Who do 
you feel should be involved? 
o Who would be your support/who would you talk to regarding the result? 
 
7) Is there anything else you would want to share with me that I haven’t asked about?    
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APPENDIX B – PARTICIPANT INFORMATION SHEET 
 
Dear Parent, 
My name is Angelique Diedericks and I am a student at the University of Cape Town, doing a 
Master’s degree in Genetic Counselling. 
As previously explained, this study aims to examine the perspectives and understanding of 
parents whose children are participating in the NeuroDev study, regarding the feedback process 
and anticipated contributions of individual genetic findings of significant neurodevelopmental-
related variants. 
This study has been initiated through the Division of Human Genetics at the University of Cape 
Town and is for a minor dissertation for the completion of a Master’s degree in Genetic 
Counselling. 
You have been invited for involvement in this research because: 
- You are part of the NeuroDev South Africa Study and have given your permission for me to 
contact you for participation in my study, whereafter a time and date for this interview was 
arranged 
 
As you have agreed to participate, I would like to talk to you about your perceptions and 
understanding of the NeuroDev study, your reasons for wanting to participate, and your 
preferences for receiving results, if any. The discussion will take about an hour, expectedly at Red 
Cross War Memorial Hospital, and R100 per individual parent or R250 voucher per family present 
for interviewing will be offered for transport. The interview will be audio- recorded and any 
identifying information, such as your name, will be kept confidential and only be known by the 
researcher and, only if necessary, her supervisors. Some parts of the audio-recorded interview 
may be used in reporting of this study but identifying information will be kept confidential. 
Your participation is entirely voluntary and you can withdraw from the study at any point, with no 
consequences for either you or your child. This being a research study, there will be no medical 
benefits to you or your child. Some of the questions that will be asked may be of a sensitive 
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manner. If you need further assistance in this regard, referral to appropriate health care 
professionals will be arranged. 
The Human Research Ethics Committee at the Faculty of Health Sciences, University of Cape 
Town, has approved this study. If you have any questions about your rights as a participant, 
please contact  Prof Marc Blockman, Chair of the Human Research Ethics Committee on 021 406 
6496. 
Should you have any questions about the research project, please contact me at 
DDRANG001@myuct.ac.za or by phone at 021 404 6235 or the project supervisor Dr. J. De Vries 
at jantina.devries@uct.ac.za or by phone at 021 650 5716. 
Please read the Consent Form attached.   
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APPENDIX C – CONSENT FORM 
MSc (Med) Genetic Counselling Research Project 
 
Qualitative exploration of the preferences of results disclosure of the parents of children 
undergoing genome sequencing in the NeuroDev study in the Western Cape, South Africa 
 
STATEMENT BY PARTICIPANT 
 
I, _______________________________________________ confirm that: 
 
1. I have been invited to be involved in the above-mentioned research project which has 
been initiated through the division of Human Genetics at the University of Cape Town. I 
understand that ~30 - 40 other adult participants will be involved in the study and that my 
name and other personal information will not be discussed with the other participants or 
with anyone else not involved in the study. 
 
2. I understand that the objective of the study is to understand how individuals, in the Western 
Cape Province of South Africa, perceive genomic testing and what their preferences are 
regarding the return of research results involving their children. 
 
3. I understand that the interview will take place in a private setting at Groote Schuur Hospital 
(GSH), Red Cross War Memorial Children’s Hospital (RXH) or in a private setting on a 
pre-scheduled date and time that is agreeable for me, the participant, and the researcher. 
 
4. I understand the interviews will take approximately 60 minutes. Should it be required that 
the interview run for longer than this allocated time, I, the participant, would be invited to 
return at my earliest convenience to continue the interview and such transport costs shall 




5. I understand that I voluntarily choose to participate in this study and if I choose to no longer 
continue that my decision will not in any way affect the health care services my child 
currently receive at RXH or any other health care institution. 
 
6. I understand that the questions may cause emotional reactions and that I may choose not 
to answer any questions if I do not wish to do so. I understand that I may decide to stop 
with the interview process at any point if I feel uncomfortable or too emotional and that this 
will not impact on my preexisting and future healthcare in any way. A genetic counselling 
session can be arranged if I would like to discuss anything further. 
 
7. I understand that all information collected will remain confidential and will be used for 
research purposes only. 
 
8. I understand that the interview will be recorded for research purposes. All audio recordings 
will be safely stored away in locked cupboards and information stored on a password-
protected computer. I understand that only the researcher, her supervisors and examiners 
will have access to the data. All recordings will be destroyed upon completion and 
publication of this study and all identities will remain anonymous. 
 
9. I understand that the interview will take place in English and that the researcher will be 
administering the interviews herself and if I do not feel comfortable communicating in 
English and require a translator, a suitably trained individual will be used to translate the 
interview and supplementary documentation. 
 
10. I understand that this study has been approved by the registered Human Research Ethics 
Committee at the Faculty of Health Sciences at the University of Cape Town. I have been 





11. I have the researcher’s contact details in the event that I would like to contact her regarding 
further questions about this study. 
 
12. _____________________________ has explained the information of this study in English or 
in _____________________________ through the use of a suitable translator and I 
understand this information. 
 
 
I ______________________________________________________ (participant name) hereby declare 
that I have voluntarily agreed to participate in the above-mentioned research study and that the 
interview can be audio-recorded. 
 
Signed at: 
(Address of venue) __________________________________ on __________________________ 
2019. 
 
Participant Name                           Witness Name 
 
Participant Signature                                                Witness Signature 
 
 
THANK YOU FOR YOUR PARTICIPATION!   
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APPENDIX D – INTERPRETER CONFIDENTIALITY & NONDISCLOSURE 
AGREEMENT 
 
INTERPRETER CONFIDENTIALITY & 
NONDISCLOSURE AGREEMENT 
 
I, ______________________ understand that when employed as an Interpreter, my responsibility is 
to facilitate communication between two or more parties that do not speak or understand the same 
language. All information discussed between the parties is considered to be “confidential”. 
 
I agree to hold confidential or proprietary information in trust and confidence and agree that 
information discussed at a meeting/activity shall be used only for the purposes of conducting such 
meeting/activity and shall not be used for any other purpose or disclosed to a third party. 
 
Furthermore, at the conclusion of the meeting/activity, I agree to return all written information (i.e., 
forms, notes, etc.) provided to me for the purposes of conducting such meeting/activity. 
 








____________________________  _______________________ 








APPENDIX E – DESCRIPTION OF CODES OUTLINED AS PER RESULTS THEME 
AND SUB-THEME 
 
4 Chapter 4 RESULTS – PARTICIPANT UNDERSTANDING, EXPECTATIONS & REASONS FOR PARTAKING IN 
GENOMIC RESEARCH  
4.1 Sociodemographic data  
4.2 Theme 1 | People want to know  
  Findings that have preventable implications 
4.3 Theme 2 | Reasons to participate in/support genomic research  
4.3.1 Altruism  
  Helping others  
- To accept condition 
- Increased support 
Increase access to resources – for prevention 
Meeting other parents and self-advocacy 
Results won’t change anything 
 
4.3.2 Participating for personal or family benefit  
  Decrease the risk of developing the condition/prevent it from happening 
  To prepare or plan for the future 
  To increase intervention 
  Cure or treatment 
 
4.4 Theme 3 | Expectations about the impact of the NeuroDev research study & general study results  
4.4.1 Best chance in life  
  Education 
  Cure or improved outcome 
  Understanding prognosis and how to support their child 
  Information and support through NeuroDev 
 
4.4.2 Establishing certainty  
  Obtain direction about future treatment and management 












4.4.3 Fulfilling the need for information  
Understanding the nature of Autism 
Understanding what causes Autism (‘why’) – maternal health vs. environmental 
triggers (e.g. vaccinations) 
How to support and manage child 
Self-empowerment 
Acceptance through diagnostic closure 
Reduce risk of recurrence 
Feeling let down by healthcare system in general 
 
4.5 Theme 4 | Understanding the study  
  Only receiving positive results 
  Issues of terminology (positive vs. negative meaning) 
  Understanding of genetics and DNA  
   -  ‘runs in families’ 
-  ‘occurring for first time in the child’ 
   
Beliefs over cause of child’s condition  
- Environmental 
- Genetic 
- ‘Many things that come together at one point’ 
 
4.5.1 Expectations of Nature of results  
  Causative 
  Confirming an inherited genetic cause 
  Environmental cause such as exposure 
 
4.5.1.1 Uncertainty over nature of study results and its implications  
  Meaning of results depends on kinds of results 
  Uncertain 
  Not expecting results 
- Reasons: 
o NeuroDev study is for data collection only 













4.5.1.2 Perceived utility of receiving non-Pertinent results  
  Participants want: 
   All results, good or bad 
- Reasons:  
o To plan for future 
o Provide quality of life 
o Inform personal health risk 
o Promote future research 
o Information discovery 
Results of significance to their child’s health 
  All results including IF 
- Reasons:  
o Warn of child’s potential health risk 
o Inform of personal health 
o Inform of future intervention 
o Better quality of life by being prepared and planning for their family’s 
future 
   All results including VUS’ 
- Reasons: 
o Future research 
   Don’t want VUS’ 
- Reasons: 
o Unsure of usefulness and concern over new information discovery 
o Potential to create anxiety 
   Negative results 
- Reasons: 
o Could reassure researchers did all they can 
o Confirmation of acknowledgement from the healthcare system 
o Personally having done all they can 
 
5 5 Chapter 5 PERTINENT RESULTS  
5.1 Theme 5 | Expectations About the Impact of Pertinent Study Results  
  Personal value of results 
- Closure 
- Improved management for their child’s condition 
- Information regarding recurrence risks 
 
5.1.1 [Diagnostic] closure  
5.1.1.1 Acceptance  
  Awareness and acceptance – form of peace 
  Relief regardless of the meaning of the result or cause of condition 
  A name for child’s condition 







5.1.1.2 Guilt and (self-)blame  
  Understanding why this happened and where it stems from 
  Put unknown to rest and move on, knowing they are not the cause 
Grief and guilt relieved by knowledge gained by participating in the study or 
comfort of knowing help is available 
  Internal guilt over carrying this genetic flaw and passing it on 
- Relieved by knowing it is a spontaneous, new occurrence in child 
- Won’t take guilt away 
Confirmation that they are not personally to blame 
Reproductive decision-making and blame 
 
5.1.1.3 Self-empowerment – what’s in a name?  
  A name for their child’s condition 
- Defined management and treatment 
- Conducting their own research 
 
5.1.2 Improving the management of child’s condition  
Becoming as educated as possible and have greater understanding of their 
child’s condition 
Would make things easier, raising hopes for treatment, medicine and an 
improved life for their child 
  A genetic diagnosis would not change the fact that the child has the condition 
 
5.1.3 Recurrence risks  
  Inform participants of personal or their children’s  reproductive potential  
- Reasons:  
o To have more children 
o To help next generation of their family 
Inform recurrence risk of affected child’s future offspring 
 
5.1.4 Results won’t change anything  
  Won’t change how they relate to their child and the condition 














6 Chapter 6 PREFERENCE TO FEEDBACK  
6.1 Theme 6 | The value of a negative result – acknowledging personal utility  
  Want to know if there are no results 
- Reason:  
o to guide future planning 
 
  Want to be contacted with a negative result 
- Reasons:  
o Getting closure 
o Peace of mind 
o Keeping calm 
o Stay informed of research progress 
o Reassurance they did the best they could 
o Sense of entitlement over their blood 
 
Participants appreciation of feedback 
 
Meaning of a negative result:  
- An answer in itself 
o Religious factors influencing meaning 
  Negative results could bring: 
- Closure 
- Peace and acceptance 
 
6.2 Theme 7 | Preferences for explanation of preliminary results  
6.2.1How much is too much?  
  Preference to second sample contact: 
- Broad explanation 
    Includes:  
 Reasons for second sample 
 What it would be for – was first sample tainted or do 
researchers need more information 
 Generic information – likely results which need to be verified 
    Reasons:  
 Eliminate worry and anxiety 
 
- Detailed explanation 
    Includes: 
 All information including what the preliminary result is that 
requires verification 
 Result explained in comprehensible manner 
 Researcher transparency regarding any uncertainty over 
meaning of results 
Reasons: 
 To be aware of findings and the process 
 To see which tests were done and what treatment is available 
 To be a part of the process 
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 To be kept informed regarding progression of the study 
 
- Don’t want to know what was found at this stage 
 
- Would know pertinent variant was found if contacted for second sample 
o Impact on participant 
 
6.3 Theme 8 | Timing Of Feedback  
  When should they be told of their results 
- After verification  
o Reasons: 
 Avoid unnecessary stress and worry over inconclusive results 
 Need for certainty 
 Maintaining peace of mind – even willing to wait longer for 
results 
 
- Before verification 
o Reasons: 
 Need for study involvement 
 To prepare for possible outcome 
 To know if they need to be concerned 
 Desire to assist in the research being conducted 
 The right to know and be informed 
 To cure or treat their child – early intervention 
 
6.3.1 Who should explain results - Familiarity  
  No preference - anyone 
  Original study researchers 
  Someone capable of explaining everything in an understandable manner 
  Someone the participant is familiar with and who listens 
 Someone who is familiar with their child, knows child’s background and who 
 participants are comfortable with asking questions 
  Their doctor or GP 
  A doctor involved in child’s management – RCWMCH doctors 
    
- Want to be told:  
o Thorough explanations 
o Reassurance  
 
NeuroDev researchers 
- Would foster ease 
- Could answer all their questions 
- Have knowledge and insight of child’s medical background and journey  




6.3.2 Where & how – Respect & Confidentiality 
Where they would like to receive feedback after verification: 





- Over the phone for negative results
- Not over the phone
o Reasons:
Distrust of technology and fear of breach of security 
- In person
o Reasons:
Would alleviate anxiety and worry 
- Letter or email explaining (child undiagnosed)
o Reasons:
Wouldn’t change management or treatment 
Sharing of their information: 
- Value confidentiality
- Anxiety about sharing private information on public databases or telephonically
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